US20080058886A1 - Implantable medical device having pre-implant exoskeleton - Google Patents
Implantable medical device having pre-implant exoskeleton Download PDFInfo
- Publication number
- US20080058886A1 US20080058886A1 US11/981,008 US98100807A US2008058886A1 US 20080058886 A1 US20080058886 A1 US 20080058886A1 US 98100807 A US98100807 A US 98100807A US 2008058886 A1 US2008058886 A1 US 2008058886A1
- Authority
- US
- United States
- Prior art keywords
- sleeve
- exoskeleton
- medical device
- insert
- sealing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37217—Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
- A61N1/37223—Circuits for electromagnetic coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/37512—Pacemakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/37516—Intravascular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/37518—Anchoring of the implants, e.g. fixation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37205—Microstimulators, e.g. implantable through a cannula
Definitions
- the present invention generally relates to devices or systems implanted within the body for therapeutic and/or diagnostic purposes.
- the invention provides methods and devices for facilitating implantation of such systems within the patient's vasculature.
- ICDs implanted cardioverter defibrillators
- Pacemakers are implanted in patients who have bradycardia (slow heart rate).
- the pacemakers detect periods of bradycardia and deliver electrical stimuli to increase the heartbeat to an appropriate rate.
- ICDs are implanted in patients who may suffer from episodes of fast and irregular heart rhythms called tachyarrhythmias.
- An ICD can cardiovert the heart by delivering electrical current directly to the heart to terminate an atrial or ventricular tachyarrhythmia, other than ventricular fibrillation.
- An ICD may alternatively defibrillate the heart in a patient who may suffer ventricular fibrillation (VF), a fast and irregular heart rhythm in the ventricles.
- VF ventricular fibrillation
- the heart quivers and can pump little or no blood to the body, potentially causing sudden death.
- An ICD implanted for correction of ventricular fibrillation will detect a VF episode and deliver an electrical shock to the heart to restore the heart's electrical coordination.
- AF atrial fibrillation
- atria upper chambers
- An electrophysiological device implanted for correction of atrial fibrillation will detect an AF episode and deliver an electrical shock to the atria to restore electrical coordination.
- Pacemakers and ICDs are routinely implanted in the pectoral region either under the skin (subcutaneous) or under the pectoral muscle.
- the leads are placed at appropriate locations around, within or on the heart. Because of this complexity, a cardiologist identifying a heart rhythm condition may be required to refer his or her patient to sub-specialists or surgeons for implantation of a pacemaker or ICD—thus delaying implantation of the device in a patient who urgently needs it. It is thus desirable to simplify these devices and the procedures for implanting them so as to permit their implantation by a broader range of physicians.
- the systems described in the '971, '113 and '223 applications include at least one housing containing the necessary circuitry and related components for delivering a charge to the heart for pacing, and/or defibrillation, etc.
- the systems may also include ‘at least one’ electrode lead through which the electrical energy is delivered to the body.
- Some or all of these components are positioned within the vasculature, such as in the superior vena cava (“SVC”), the inferior vena cava (“IVC”), or the left or right subclavian, coronary sinus, and/or other vessels of the venous or arterial systems.
- the housing containing electronics, circuitry, batteries, capacitors, etc.
- LSV left subclavian vein
- IVC left subclavian vein
- coronary sinus of the heart and/or the right ventricle of the heart.
- Retention devices may be used to retain some of these components within the vasculature.
- the present disclosure describes components that facilitate implantation and later removal of the housing containing electronics, circuitry, batteries, etc. in an intravascular system.
- the application describes a sleeve or “exoskeleton” that is implanted in the vasculature.
- the exoskeleton may be retained in place using a retention device.
- the housing is inserted into the exoskeleton. If at some date it becomes necessary to explant the housing, it may be withdrawn from the exoskeleton and removed from the body, leaving the exoskeleton in place.
- FIG. 1 is a perspective illustration showing human cardiac anatomy.
- FIG. 2 is a plan view generally showing components of a first embodiment of intravascular defibrillation and/or pacing system and associated implantation tools.
- FIG. 3A is a plan view of a distal portion of the exoskeleton of FIG. 2 .
- FIG. 3B is a plan view of the exoskeleton and insert of FIG. 2 , showing an alternative arrangement of electrical contacts.
- FIG. 3C is a plan view of an insert positioned within an exoskeleton, showing a third arrangement of electrical contacts.
- FIG. 4A is a plan view of an insert.
- FIG. 4B is a plan view of a distal portion of an exoskeleton assembled with an insert. The exoskeleton is shown in cross-section.
- FIGS. 5A through 5E are a sequence of schematic views of a heart and associated vasculature, illustrating an implantation method using the system of FIG. 2 .
- FIG. 5F is a schematic view similar to the FIG. 5A-5E views illustrating removal of the insert.
- FIG. 6 is an elevation view showing an alternative embodiment of an exoskeleton and insert.
- FIG. 7 is a side elevation of an alternative insert.
- FIG. 8A is a front elevation view showing an alternative exoskeleton.
- FIG. 8B is a side elevation view showing an alternative insert for use with the exoskeleton of FIG. 8A .
- FIG. 8C is a side elevation view showing the components of FIGS. 8A and 8B in assembled form.
- FIG. 9 is a cross-sectional side view of another embodiment of an exoskeleton and insert.
- FIGS. 10A and 10B illustrate various electrode and contact embodiments useful for exoskeletons.
- FIG. 11 illustrates an alternative embodiment of an exoskeleton and insert which form part of an intravascular drug delivery system.
- FIG. 1 shows the cardiac anatomy of a human, including the heart and major vessels.
- the following anatomic locations are shown and identified by the listed reference numerals: Right Subclavian 2a Left Subclavian 2b Superior Vena Cava (SVC) 3a Inferior Vena Cava (IVC) 3b Right Atrium (RA) 4a Left Atrium (LA) 4b Right Atrial Appendage (RAA) 5 Coronary Sinus Ostium (CS Os) 6 Right Ventricle (RV) 7a Left Ventricle (LV) 7b Aortic Arch 8 Descending Aorta 9
- Exoskeleton configurations will be described in the context of an intravascular system useful for electrophysiological (“EP”) applications (such as implantable defibrillation systems and associated components), it should be appreciated that the disclosed embodiments and methods or variations thereof may be used to implant other types of intravascular systems, including but not limited to pacing, defibrillation or cardioversion systems.
- the components may find further use in connection with intravascular systems for delivering other forms of therapy (e.g., pharmaceutical therapies) to the body.
- Such systems are described in U.S. application Ser. No. ______, INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS, filed Dec. 9, 2004, Attorney Docket No. NMX-110, the entirety of which is incorporated herein by reference.
- exoskeleton components may be useful include intravascular diagnostic systems such as those that monitor blood glucose, blood oxygen, or other parameters. It should also be mentioned that although this application describes the systems for use in the vasculature, pre-implant exoskeletons may be implanted at other sites within the body where medical implants are to be placed. For example, exoskeletons may function as pre-implant devices in subcutaneous pockets or in organs or body cavities throughout the body.
- FIG. 2 generally shows one example of an intravascular defibrillation system 10 of a type that may utilize components of the type described herein.
- the elements of system 10 include a defibrillation and/or pacing device 12 , which is comprised of a tubular exoskeleton 13 a and an insert 13 b that is slidably received within an opening 15 a in the exoskeleton.
- Exoskeleton 13 a may function as a “pre-implant”, i.e., a sleeve or shell that is first anchored within a vessel, whereas insert 13 b serves to house the electronics and associated features for carrying out the system functions.
- the exoskeleton 13 a is proportioned to be passed into the vasculature and to be anchored within the patient's vasculature with minimal obstruction to blood flow.
- Suitable sites for the exoskeleton may include, but are not limited to the venous system using access through the right or left femoral vein or the subclavian or brachiocephalic veins, or the arterial system using access through one of the femoral arteries.
- the exoskeleton preferably has a streamlined maximum cross sectional diameter which may be in the range of 3-15 mm or less, with a most preferred maximum cross-sectional diameter of 3-8 mm or less.
- the cross-sectional area of the exoskeleton in the transverse direction should be as small as possible while still accommodating the required components within the insert 13 b .
- This area is preferably in the range of approximately 79 mm 2 or less, and more preferably in the range of approximately 40 mm 2 or less, or most preferably between 12.5-40 mm 2 .
- the exoskeleton preferably forms a fluid-tight barrier against migration of body fluids into its interior. Avoiding leakage of blood and body fluids avoids thrombus formation and endothelial or cellular growth within the exoskeleton and onto the insert, and thus allows the insert to be removed from the exoskeleton when necessary for replacement or servicing.
- materials useful for the exoskeleton include PTFE, ePTFE, PFPE, other fluropolymers, polyurethanes, silicone, polyolefin rubber, dacron polyester, PET, PMMA, EVA or polypropylene, ceramics, surface reactive glass ceramics (including bioglasses or bioceramics), or metals including titanium and its alloys and/or other biocompatible metals.
- Exoskeleton 13 a may be formed of a polymeric material having a reinforcing structure (e.g., a metallic or polymeric braid) over, under or integrated with the polymeric material.
- a reinforcing structure e.g., a metallic or polymeric braid
- One example of this type of arrangement would be a braid lined with a Teflon polymer.
- a tissue growth e.g., cellular encapsulation, in-growth, endothelialization
- Tissue growth onto/into the exoskeleton can improve the stability of the exoskeleton within the vessel, and may improve the biocompatibility of the system within the vessel by improving blood-surface compatibility.
- Cellular growth may be encouraged by giving the exoskeleton an in-growth promoting surface using structural features.
- the exterior surface of the exoskeleton may have pores (e.g., from a porous material), interstices (e.g., in a mesh material), or other surface modifications into or onto which cellular growth can occur.
- the exoskeleton may have an exterior surface formed or covered by Dacron or by a form of ePTFE having a node to fibril length of approximately 15-25 microns.
- Cellular growth into or onto the exoskeleton may also be promoted using a substance that promotes in-growth.
- the exoskeleton may be coated or impregnated with a substance such as albumen, growth factors, synthetic or natural therapeutic molecules, or any other substance that will promote cellular growth.
- the exoskeleton may be formed of a material or covered by a layer or coating having anti-proliferative properties so as to minimize endothelialization or cellular ingrowth, since minimizing growth into or onto the device will help minimize vascular trauma when the device is explanted.
- a form of ePTFE having a note-to-fibril length of approximately 1-10 microns, and preferably less than approximately 10 microns, may be used for this purpose.
- the exoskeleton may be constructed such that it will degrade over a period of time calculated such that degradation will occur after the intended useful life of the insert.
- Materials suitable for this purpose include LPLA, polyglycolic acid, polydioxanone, polyanhydrides or other erodable materials. According to this embodiment, degradation of the exoskeleton would preferably be timed to occur following removal of the implant.
- the exoskeleton surface may also be anti-thrombogenic (e.g., using materials or coating such as perfluorocarbon coatings applied using supercritical carbon dioxide), although if cellular ingrowth is desired some thrombosis may be allowed as a substrate for endothelial growth.
- the exoskeleton may also include a surface or coating, which elutes compositions, such as anti-thrombogenic compositions (e.g., heparin sulfate) and/or anti-proliferative compositions and/or immunosuppressive agents.
- the most proximal section of the device may include a transition 17 a to a more flexible tail section 17 b of the exoskeleton, which may be coiled and tucked into a subcutaneous pocket following implantation as will be discussed below.
- the insert 13 b may fit snugly into the exoskeleton 13 a , in which case the exoskeleton may function as a coating on the insert 13 b.
- Electrodes leads 14 may extend as branches from the exoskeleton 13 a .
- Leads include electrodes 16 for delivering electrical energy to the surrounding body tissue.
- the lead 14 may be positionable with in the right ventricle (RV) of the heart.
- Additional electrodes may be positioned on the body of the exoskeleton.
- the exoskeleton may include electrodes 18 a positionable within the left subclavian vein (LSV) 2 b , and electrodes 18 b positionable within the inferior vena cava (IV C) 3 b.
- LSV left subclavian vein
- IV C inferior vena cava
- the term “exoskeleton” is not intended to mean that the exoskeleton 13 a is necessarily hard or rigid. As discussed, the exoskeleton preferably forms a barrier against migration of body fluids into contact with the insert, but it need not be a rigid barrier. In a preferred embodiment the exoskeleton is sufficiently flexible to be passed through the vasculature. However, certain sections of the exoskeleton 13 a may include additional features that supplement the strength and stability of those sections after they have been positioned at their final location within the vasculature. This may be desirable during removal of the insert 13 b from the exoskeleton 13 a to assist the exoskeleton 13 a in resisting axial forces applied against it during withdrawal of the insert.
- One reinforcement method might include providing the exoskeleton with pockets of curable or reactive polymer in a liquid state. These pockets might be positioned throughout the exoskeleton, or at select regions such as the lead 14 , and/or the bifurcation 11 , and points distal to the bifurcation 11 .
- the polymer Once the exoskeleton is positioned or just prior to extraction of the insert, the polymer would be cured using the appropriate curing method (e.g., UV exposure, chemical contact, thermal activation, etc.).
- the cured material can help the exoskeleton to retain a desired shape within the vessel, and can assist with axial stability.
- Another embodiment of a reinforcement method might involve inserting reinforcing wires or ribbons through lumens in the sidewalls of the exoskeleton following implantation of the exoskeleton or just prior to extraction of the insert.
- the interior surface of the exoskeleton includes a plurality of electrical contacts 19 a, b, c .
- Each of the contacts 19 a , 19 b , 19 c is connected to a corresponding wire 20 a , 20 b , 20 c that extends through the exoskeleton (e.g., through the main lumen or though channels in the sidewalls of the exoskeleton).
- Each wire is in turn coupled to one of the electrodes or electrode arrays 16 , 18 a , 18 b .
- FIG. 3A also illustrates an alternative form of electrodes that differ from the surface electrodes shown on the FIG. 2 embodiment. In the FIG.
- each wire e.g., wire 20 a
- each wire extending through the exoskeleton penetrates the wall of the exoskeleton and is wound on the surface of the exoskeleton to form the electrode.
- Sealing compound is preferably used to seal the exoskeleton at the point of penetration.
- the insert 13 b is a hermetically sealed housing containing electronics and other features necessary for the operation of the system. These features may include one or more pulse generators, including associated batteries, capacitors, microprocessors, and circuitry for generating defibrillation pulses. Detection circuitry for detecting arrhythmias or other abnormal activity of the heart may also be housed within insert 13 b .
- the housing may be made from metals such as titanium or titanium alloys, polymers, or other suitable materials.
- the exoskeleton will preferably isolate the insert from body materials, the insert may be covered by a layer or coating having anti-proliferative properties so as to minimize endothelialization or cellular ingrowth onto the insert in the event some fluids migrate into the exoskeleton.
- One or more electrical contacts 22 a , 22 b , 22 c are positioned on the exterior surface of the insert 13 b .
- the contacts 22 a , 22 b , 22 c may take the form of conductive elements attached to the housing of the device insert.
- the contacts may be formed by selectively applying the coating or removing portions of the coating to leave one or more exposed contact regions on the surface of the insert.
- Contacts 22 a , 22 b , 22 c are positioned to electrically couple to the corresponding contacts 20 a , 20 b , 20 c ( FIG. 3A ) inside the exoskeleton when the device 12 is fully assembled.
- electrical energy emitted by the pulse generator within the housing is directed to the appropriate electrodes 16 , 18 a , 18 b on the exoskeleton.
- any electrodes are positioned to detect the heart's electrical activity, are electrically coupled to detection circuitry within the insert 13 b.
- FIG. 3B illustrates alternative positioning of the contacts 19 a, b, c and the contacts 22 a , 22 b , 22 c .
- the FIG. 3B embodiment positions contacts 19 b , 22 b in the region of the LSV electrode 18 a , and contacts 19 c , 22 c in the region of the IVC electrode 18 b .
- the contacts 19 a , 22 a for the RV electrode 16 are positioned near the bifurcation of the lead 14 .
- the insert 13 b need not be proportioned to extend to the distal end of the exoskeleton. However, the insert 13 b may be long enough to extend to the distal end even if it not necessary for making electrical contact.
- FIG. 3C illustrates the distal portion of insert 13 b disposed within the distal portion of exoskeleton 13 b .
- the walls of the exoskeleton are shown in cross-section to allow the insert to be seen.
- a tiered structure is used for the distal portions of the insert and exoskeleton with conductive rings forming contacts 19 e , 22 e at each tier 7 . More specifically, at each tier 7 a conductive ring 19 e lines the interior surface of the exoskeleton 13 b , and a corresponding conductive ring 22 e lines the exterior surface of the insert 13 a .
- the tiers may be proportioned such to create an interference fit between the insert and the exoskeleton.
- the system may include alternative features that engage the insert 13 b within the exoskeleton 13 a .
- the retention forces between the exoskeleton and insert are preferably sufficient to retain the insert, but also such that they may be overcome by manually withdrawing the insert 13 b .
- the interior surface of the exoskeleton and/or the exterior surface of the insert may include raised elements (e.g., rib features, broadened sections etc.) that cause the two components to engage due to friction forces between adjacent surfaces.
- FIG. 4A illustrates raised elements 23 on the surface of the insert 13 b .
- the general fit between the components 13 a , 13 b may be sufficient to create such friction.
- one or more of the contacts within the exoskeleton 13 a may take the form of a metallic leaf spring radially biased towards the central axis of the exoskeleton. This is illustrated in FIG. 4B .
- the contacts 19 b are inwardly biased leaf springs.
- the electrodes 18 a may be strips of conductive material or sections of conductive tubing electrically coupled to the contacts 22 b using rivets 21 or other conductive elements passing through the wall of the exoskeleton. As shown, when the insert is placed within the exoskeleton, leaf spring contact 19 b springs into engagement with a corresponding contact 22 b on the insert 13 b .
- the contact 22 b may be positioned within a recess formed in the surface of the insert 13 b as shown.
- a plurality of similar leaf springs (which may or may not be conductive) may be used at one or more locations on the exoskeleton surface to ensure that engagement between the components is secure.
- FIGS. 10A and 10B Some alternative electrode and contact designs similar to the FIG. 3A design are shown in FIGS. 10A and 10B . It should be mentioned that the configurations for the electrodes and associated contacts described in this application are merely examples and not given as an all-inclusive list.
- an electrode 18 d comprises a wire coil, wherein a first portion of the coil is positioned within the exoskeleton to form a contact 19 d that makes contact with a corresponding contact on the insert. A second portion of the coil is wrapped around the exterior surface of the exoskeleton for contact with tissue.
- the electrode 18 e is formed of a strand wire wound in an undulating pattern. A portion of the pattern is positioned inside the exoskeleton to serve as contact 19 e , whereas another portion extends through the exoskeleton wall to form the external electrode. A similar pattern may be cut into a sheet or tube of metal rather than looped using a wire. The contact portion 19 e of the wire may be biased inwardly in a manner similar to the leaf springs 19 b of FIG. 4B
- Anchor 24 includes structural features that allow the anchor to self-expand into radial engagement with a vessel wall.
- a band, mesh or other framework formed of one or more shape memory (e.g., nickel titanium alloy, nitinol, thermally activated shape-memory material, or shape memory polymer) elements or stainless steel, Elgiloy, or MP35N elements may be used.
- shape memory e.g., nickel titanium alloy, nitinol, thermally activated shape-memory material, or shape memory polymer
- the anchor 24 is preferably constructed to promote tissue ingrowth to as to enhance anchor stability within the vessel.
- Structural features such as mesh or other framework configurations are suitable for this purpose, although compositions and/or coatings that promote in-growth may also be used.
- a retractable sheath 26 may be slidably positioned over the anchor 24 and the exoskeleton 13 a so as to retain the anchor in its compressed position. (The sheath 26 may also be used to hold the lead branch 14 streamlined against the exoskeleton 13 a during implantation.) Retraction of the sheath once the exoskeleton is properly positioned allows the anchor 24 to expand into contact with the surrounding walls of the vessel, thereby holding the exoskeleton in the desired location. Once deployed, the anchor 24 is preferably intimate to the vessel wall, which is distended slightly, allowing the vessel lumen to remain approximately continuous despite the presence of the anchor and thus minimizing turbulence or flow obstruction. Although self-expansion of the anchor is preferable, mechanical expansion means (e.g., balloon expanders etc) may be used for active expansion of the anchor.
- mechanical expansion means e.g., balloon expanders etc
- the anchor may also have drug delivery capability via a coating matrix impregnated with one or more pharmaceutical agents.
- the anchor 24 may be configured such that the exoskeleton 13 a and anchor 24 share a longitudinal axis, or such that the axes of the exoskeleton 13 a and anchor 24 are longitudinally offset.
- An implantation mandrel 28 is attachable to the proximal end of exoskeleton 13 a (e.g., at transition region 17 a ) for advancing the exoskeleton into position within the body.
- the mandrel 28 may also be used to push the insert into the exoskeleton or a separate tool can be used for this purpose.
- the system may additionally be provided with other components useful for implanting the system, including guidewires 30 a , 30 b and an introducer 32 .
- the exoskeleton will preferably include guidewire lumens that permit tracking of the exoskeleton over the guidewires, or openings formed at the distal end of the exoskeleton and/or lead 14 for receiving the guidewires.
- the distal openings would preferably include seals to prevent migration of blood or other body fluids into the exoskeleton.
- the openings might instead include one-way valves that allow any body fluids that pass into the exoskeleton to be purged from the exoskeleton using a fluid (e.g., saline or carbon dioxide gas) injected into the proximal opening 15 .
- FIGS. 5A through 5E illustrate implantation of the system 10 of FIG. 2 .
- the exoskeleton is implanted first, and then the insert is passed into the exoskeleton.
- the insert may be passed into the exoskeleton outside the body and the two components introduced simultaneously.
- a small incision is first formed in the femoral vein and the introducer sheath 32 is inserted through the incision into the vein to keep the incision open during the procedure.
- guidewires 30 a , 30 b are passed through the sheath 32 and into the inferior vena cava 3 b .
- Guidewire 30 a is steered under fluoroscopy into the left subclavian vein 2 b and guidewire 30 b is guided into the right ventricle 7 a of the heart.
- only guidewire 30 b is used and is advanced into the right ventricle 7 a.
- the lead 14 ( FIG. 2 ) is threaded over guidewire 30 b by extending the guidewire into the exoskeleton and out of the exoskeleton via an opening in the lead 14 . If both guidewires are used, the distal end of the exoskeleton 3 b is threaded over guidewire 30 a . The lead 14 and the distal end of the exoskeleton 13 a are then passed through the introducer sheath 32 and into the IVC 3 b . See FIG. 5A . Pushing on the exoskeleton causes the lead 14 to track over guidewire 30 b while the exoskeleton advances within the vasculature (and over guidewire 30 b if used).
- the guidewires 30 a , 30 b are withdrawn. If necessary, a fluid such as saline or CO2 is directed through exoskeleton as described above to purge any body fluids from the exoskeleton.
- a fluid such as saline or CO2 is directed through exoskeleton as described above to purge any body fluids from the exoskeleton.
- implantation mandrel 28 is attached to the proximal portion of the exoskeleton 13 a (e.g., at transition region 17 a ) and is used to push the exoskeleton further into the vasculature. Advancement of the mandrel 28 is continued until the distal portion of the exoskeleton reaches the desired position within the LSV 2 b , and the lead 14 had tracked the guidewire 30 b into the right ventricle 7 a as shown in FIG. 5B . At this stage, some of the flexible tail section 17 b of the exoskeleton remains outside the body.
- the exoskeleton is next anchored in place by releasing the anchor 24 to its expanded position as shown in FIG. 5C .
- the anchor expands into contact with the surrounding vessel wall, thereby preventing migration of the exoskeleton.
- the distal portion of exoskeleton 13 a may be anchored in the LSV 2 b using another suitable anchor.
- the mandrel 28 is detached from the exoskeleton and withdrawn from the body.
- the insert 13 b is inserted into the exoskeleton as shown in FIG. 5D .
- the implantation mandrel 28 may be attached to the insert 13 b and used to push the insert 13 b into position.
- the insert 13 b is advanced to a point at which the contacts on the insert 13 b have made electrical contact with the corresponding contacts of the exoskeleton.
- the mandrel 28 is removed and the opening 15 a in exoskeleton is sealed using a cap or plug 15 b , or using a sealing compound that will harden to seal the opening 15 a .
- the flexible tail section 17 b of the exoskeleton is coiled and tucked into the femoral vein or into a subcutaneous pocket adjacent to the femoral vein and is stored there for future access.
- the incision through the patient's skin is preferably closed and allowed to heal.
- Future access to the insert 13 b may be needed for a variety of reasons. For example, if the battery within the insert 13 b should become depleted, the insert may be removed and replaced with a new device, or a charging device may be coupled to the insert 13 b.
- a femoral incision is formed to gain access to the tail section 17 b .
- a sufficient length of the tail 17 b is removed from the body to permit access to the opening 15 a in the tail 17 b .
- the opening 15 a is unsealed such as by removing its cap, plug 15 b or seal.
- the exoskeleton may be re-opened by snipping off the proximal portion of the tail within which the cap, plug or seal is positioned.
- An extraction tool such as mandrel 28 may be passed into the exoskeleton and used to engage the insert.
- an alternative mandrel may be used that includes a distal coupling comprising a mouth that is significantly broader than the proximal end of the device.
- a distal coupling comprising a mouth that is significantly broader than the proximal end of the device.
- FIG. 5F An alternative extraction method is illustrated in FIG. 5F .
- a syringe 60 may be coupled to the exoskeleton 13 a and used to pump saline, carbon dioxide, or other fluid into the exoskeleton.
- fluid pressure forces the insert towards the open end of the exoskeleton.
- This step may also be combined with manual extraction using a mandrel.
- a fresh component may be inserted into the exoskeleton and will displace any fluid remaining in the exoskeleton will be driven out the opening 15 a by the advancing insert.
- FIG. 6 shows an alternative embodiment of a system 110 utilizing an exoskeleton 113 a and an insert 113 b insertable into the exoskeleton.
- leads 14 a , 14 b extend from the exoskeleton 113 a as shown.
- Each lead 114 a , 114 b is electrically connected to a contact point (not shown) that is exposed in the hollow interior of the exoskeleton 113 a .
- the contact points are positioned to make electrical contact with corresponding points 122 on the surface of the interior housing when the exoskeleton 113 a and insert 113 b are assembled.
- the exoskeleton and the insert 113 a , 113 b are preferably provided with means for securely engaging one another.
- threaded female and male connectors 40 , 42 may be provided on the exoskeleton and inserts 113 a , 113 b , respectively.
- the insert 113 a is rotated to engage the threads of the connectors.
- Additional sealing structures e.g., o-rings
- threads 42 a may be formed on the exterior surface near the distal end of the insert 113 b , with corresponding female threads on the exoskeleton (not shown).
- an implantation tool (which may be similar to mandrel 28 of FIG. 2 ) would be connectable to the insert 113 b and used for guiding the insert 113 b through the vasculature and then rotating the component 113 b to cause the corresponding threads to engage.
- insert 113 b may include a spring clip 44
- exoskeleton 113 a may include a window 46 , such that when the components are assembled the clip 44 engages with the window as shown in FIG. 8C . Since clip 44 may be exposed through the window 46 , it may be desirable to wire the clip 44 to function as an electrode on the exterior of the device.
- one or more o-ring seals 50 may be used to keep fluids out of the exoskeleton. Seals (not shown) may also be used around the clip 44 to prevent fluid leakage from entering the device 112 through the window.
- leads 214 are attached to the insert 213 b , and the exoskeleton 214 a includes openings through which the leads may be passed during implantation.
- exoskeleton 213 a includes sleeves 52 through which the leads may be passed for this purpose.
- the exoskeleton may include holes in the distal end in place of sleeves 52 . Seals (such as o-rings of the type discussed earlier) may be positioned to prevent migration of fluids into the exoskeleton via the sleeves 52 .
- leads 214 are fed through the sleeves 52 and are positioned within the heart and/or vessels in a manner similar to that described above.
- Fluid such as saline or gas such as carbon dioxide may be directed into the open proximal end of the exoskeleton to prevent inflow of blood or to displace blood that may have already have entered the exoskeleton during implantation.
- Holes or one-way valves may also be formed in the distal region of the exoskeleton to allow any blood that may have accumulated within the exoskeleton to be displaced and evacuated as the insert is passed into the exoskeleton to facilitate retention in the body.
- the exoskeleton configuration may be adapted for use with an intravascular drug delivery system of the type describe in U.S. application Ser. No. ______, INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS, filed Dec. 9, 2004, Attorney Docket No. NMX-110, which is incorporated herein by reference.
- a system includes an implantable drug reservoir, together with components that function to transfer drug from the reservoir into the bloodstream or into certain organs or tissues.
- Components used for this purpose may include pumps, motors and batteries, and/or other components such as those listed in the NMX-110 application.
- a system 310 may include an exoskeleton 313 a and an insert 313 b slidably received within the exoskeleton 313 a .
- Insert 313 b includes a drug reservoir 314 and a refill line 318 coupled to the reservoir.
- a pump system 316 directs agent to an exit tube or orifice 320 .
- Exoskeleton includes a port 322 that allows fluid released through the exit orifice 320 to pass into the bloodstream.
- a seal 324 may be positioned within the exoskeleton to prevent backflow of drug from exit orifice 320 into the exoskeleton 313 a.
- the exoskeleton may include a flexible tail portion 317 that, as described in connection with the FIG. 2 embodiment, may be tucked into the femoral vein or a subcutaneous pocket following implantation.
- a subcutaneous portal 326 is fluidly coupled to the refill line 318 of reservoir, and may also function to seal the tail 317 of the exoskeleton.
- Portal 326 may include a one-way valve (not shown) that prevents fluid from entering the exoskeleton, or it may include a seal formed of a material that will reseal itself following puncture.
- Implantation of the system 310 and replacement of the insert 313 b may be performed using techniques described above.
- the reservoir 314 may be refilled by using a refill vessel such as a recharge syringe 328 filled with the desired drug.
- the needle tip of the recharge syringe may be inserted through the skin and into the subcutaneous portal 326 .
- drug reservoir within the insert 313 b may be maintained at a negative pressure so as to draw the agent from the syringe once fluid communication is established.
- the tail 317 may be withdrawn from the body through a small incision, and the recharge syringe 328 or other refill device may be coupled to the portal 326 outside the body. In either case, the drug is then injected from the syringe into the reservoir via the portal 326 and refill line 318 . If the system 310 is provided without a refill line and portal, the insert may instead be replaced with a new component containing a fresh supply of drug using methods described above.
- the insert 313 b may be provided with a refill port in the insert body 313 b rather than a fill line 318 extending from the insert.
- a mandrel having a distal coupling including a mouth that is significantly broader than the proximal end of the device.
- the mandrel would be introduced into the exoskeleton and advanced towards the insert until it passes over the proximal end of the insert.
- the mandrel is then clamped over the proximal end of the insert to sealingly engage the insert and to create a fluid coupling between the mandrel's fluid lumen and a refill lumen into the insert.
- Drug is then introduced into the mandrel for delivery into the reservoir within the insert.
Abstract
The present application describes a method and apparatus for implanting a medical device within a living body. The apparatus includes an elongate sleeve positionable with a living body, such as within a blood vessel, and a medical device insertable into the sleeve. During use, the sleeve is retained with the body, and the medical device is sealed within the sleeve. The sleeve substantially avoids biological growth onto the medical device, and thus permits removal of the medical device independently of the sleeve.
Description
- This application claims priority from prior Provisional Application Ser. No. 60/529,051, filed Dec. 12, 2003, and which is incorporated herein by reference.
- The present invention generally relates to devices or systems implanted within the body for therapeutic and/or diagnostic purposes. In particular, the invention provides methods and devices for facilitating implantation of such systems within the patient's vasculature.
- Pacemakers, defibrillators and implanted cardioverter defibrillators (“ICDs”) have been successfully implanted for years for treatment of heart rhythm conditions.
- Pacemakers are implanted in patients who have bradycardia (slow heart rate). The pacemakers detect periods of bradycardia and deliver electrical stimuli to increase the heartbeat to an appropriate rate.
- ICDs are implanted in patients who may suffer from episodes of fast and irregular heart rhythms called tachyarrhythmias. An ICD can cardiovert the heart by delivering electrical current directly to the heart to terminate an atrial or ventricular tachyarrhythmia, other than ventricular fibrillation. An ICD may alternatively defibrillate the heart in a patient who may suffer ventricular fibrillation (VF), a fast and irregular heart rhythm in the ventricles. During a VF episode, the heart quivers and can pump little or no blood to the body, potentially causing sudden death. An ICD implanted for correction of ventricular fibrillation will detect a VF episode and deliver an electrical shock to the heart to restore the heart's electrical coordination.
- Another type of implantable defibrillation device treats patients who may suffer from atrial fibrillation (AF), which is a loss of electrical coordination in the heart's upper chambers (atria). During AF, blood in the atria may pool and clot, placing the patient at risk for stroke. An electrophysiological device implanted for correction of atrial fibrillation will detect an AF episode and deliver an electrical shock to the atria to restore electrical coordination.
- Pacemakers and ICDs are routinely implanted in the pectoral region either under the skin (subcutaneous) or under the pectoral muscle. The leads are placed at appropriate locations around, within or on the heart. Because of this complexity, a cardiologist identifying a heart rhythm condition may be required to refer his or her patient to sub-specialists or surgeons for implantation of a pacemaker or ICD—thus delaying implantation of the device in a patient who urgently needs it. It is thus desirable to simplify these devices and the procedures for implanting them so as to permit their implantation by a broader range of physicians.
- U.S. application Ser. Nos. 10/453,971 and 10/454,223 (“the '971 and '223 applications), filed Jun. 4, 2003, and 10/862,113, filed Jun. 4, 2004 (the '113 application) describe intravascular systems that may be used to deliver electrical energy to the heart such as for defibrillation, pacing, and/or cardioversion of the heart. Each of these applications is incorporated herein by reference for all purposes.
- Generally speaking, the systems described in the '971, '113 and '223 applications include at least one housing containing the necessary circuitry and related components for delivering a charge to the heart for pacing, and/or defibrillation, etc. The systems may also include ‘at least one’ electrode lead through which the electrical energy is delivered to the body. Some or all of these components are positioned within the vasculature, such as in the superior vena cava (“SVC”), the inferior vena cava (“IVC”), or the left or right subclavian, coronary sinus, and/or other vessels of the venous or arterial systems. For example, the housing containing electronics, circuitry, batteries, capacitors, etc. may be positioned in the IVC or SVC, while leads extending from the housing may extend to the left subclavian vein (LSV), the IVC, the coronary sinus of the heart, and/or the right ventricle of the heart. Retention devices may be used to retain some of these components within the vasculature.
- The present disclosure describes components that facilitate implantation and later removal of the housing containing electronics, circuitry, batteries, etc. in an intravascular system. In particular, the application describes a sleeve or “exoskeleton” that is implanted in the vasculature. The exoskeleton may be retained in place using a retention device. Following implantation of the exoskeleton, the housing is inserted into the exoskeleton. If at some date it becomes necessary to explant the housing, it may be withdrawn from the exoskeleton and removed from the body, leaving the exoskeleton in place.
-
FIG. 1 is a perspective illustration showing human cardiac anatomy. -
FIG. 2 is a plan view generally showing components of a first embodiment of intravascular defibrillation and/or pacing system and associated implantation tools. -
FIG. 3A is a plan view of a distal portion of the exoskeleton ofFIG. 2 . -
FIG. 3B is a plan view of the exoskeleton and insert ofFIG. 2 , showing an alternative arrangement of electrical contacts. -
FIG. 3C is a plan view of an insert positioned within an exoskeleton, showing a third arrangement of electrical contacts. -
FIG. 4A is a plan view of an insert. -
FIG. 4B is a plan view of a distal portion of an exoskeleton assembled with an insert. The exoskeleton is shown in cross-section. -
FIGS. 5A through 5E are a sequence of schematic views of a heart and associated vasculature, illustrating an implantation method using the system ofFIG. 2 . -
FIG. 5F is a schematic view similar to theFIG. 5A-5E views illustrating removal of the insert. -
FIG. 6 is an elevation view showing an alternative embodiment of an exoskeleton and insert. -
FIG. 7 is a side elevation of an alternative insert. -
FIG. 8A is a front elevation view showing an alternative exoskeleton. -
FIG. 8B is a side elevation view showing an alternative insert for use with the exoskeleton ofFIG. 8A . -
FIG. 8C is a side elevation view showing the components ofFIGS. 8A and 8B in assembled form. -
FIG. 9 is a cross-sectional side view of another embodiment of an exoskeleton and insert. -
FIGS. 10A and 10B illustrate various electrode and contact embodiments useful for exoskeletons. -
FIG. 11 illustrates an alternative embodiment of an exoskeleton and insert which form part of an intravascular drug delivery system. - Cardiac Anatomy
-
FIG. 1 shows the cardiac anatomy of a human, including the heart and major vessels. The following anatomic locations are shown and identified by the listed reference numerals:Right Subclavian 2a Left Subclavian 2b Superior Vena Cava (SVC) 3a Inferior Vena Cava (IVC) 3b Right Atrium (RA) 4a Left Atrium (LA) 4b Right Atrial Appendage (RAA) 5 Coronary Sinus Ostium (CS Os) 6 Right Ventricle (RV) 7a Left Ventricle (LV) 7b Aortic Arch 8 Descending Aorta 9 - Exoskeleton configurations will be described in the context of an intravascular system useful for electrophysiological (“EP”) applications (such as implantable defibrillation systems and associated components), it should be appreciated that the disclosed embodiments and methods or variations thereof may be used to implant other types of intravascular systems, including but not limited to pacing, defibrillation or cardioversion systems. The components may find further use in connection with intravascular systems for delivering other forms of therapy (e.g., pharmaceutical therapies) to the body. Such systems are described in U.S. application Ser. No. ______, INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS, filed Dec. 9, 2004, Attorney Docket No. NMX-110, the entirety of which is incorporated herein by reference. Other systems for which the exoskeleton components may be useful include intravascular diagnostic systems such as those that monitor blood glucose, blood oxygen, or other parameters. It should also be mentioned that although this application describes the systems for use in the vasculature, pre-implant exoskeletons may be implanted at other sites within the body where medical implants are to be placed. For example, exoskeletons may function as pre-implant devices in subcutaneous pockets or in organs or body cavities throughout the body.
- General Discussion
-
FIG. 2 generally shows one example of anintravascular defibrillation system 10 of a type that may utilize components of the type described herein. The elements ofsystem 10 include a defibrillation and/or pacingdevice 12, which is comprised of atubular exoskeleton 13 a and aninsert 13 b that is slidably received within anopening 15 a in the exoskeleton.Exoskeleton 13 a may function as a “pre-implant”, i.e., a sleeve or shell that is first anchored within a vessel, whereasinsert 13 b serves to house the electronics and associated features for carrying out the system functions. - The
exoskeleton 13 a is proportioned to be passed into the vasculature and to be anchored within the patient's vasculature with minimal obstruction to blood flow. Suitable sites for the exoskeleton may include, but are not limited to the venous system using access through the right or left femoral vein or the subclavian or brachiocephalic veins, or the arterial system using access through one of the femoral arteries. Thus, the exoskeleton preferably has a streamlined maximum cross sectional diameter which may be in the range of 3-15 mm or less, with a most preferred maximum cross-sectional diameter of 3-8 mm or less. The cross-sectional area of the exoskeleton in the transverse direction (i.e., transecting the longitudinal axis) should be as small as possible while still accommodating the required components within theinsert 13 b. This area is preferably in the range of approximately 79 mm2 or less, and more preferably in the range of approximately 40 mm2 or less, or most preferably between 12.5-40 mm2. - The exoskeleton preferably forms a fluid-tight barrier against migration of body fluids into its interior. Avoiding leakage of blood and body fluids avoids thrombus formation and endothelial or cellular growth within the exoskeleton and onto the insert, and thus allows the insert to be removed from the exoskeleton when necessary for replacement or servicing. Examples of materials useful for the exoskeleton include PTFE, ePTFE, PFPE, other fluropolymers, polyurethanes, silicone, polyolefin rubber, dacron polyester, PET, PMMA, EVA or polypropylene, ceramics, surface reactive glass ceramics (including bioglasses or bioceramics), or metals including titanium and its alloys and/or other biocompatible metals.
Exoskeleton 13 a may be formed of a polymeric material having a reinforcing structure (e.g., a metallic or polymeric braid) over, under or integrated with the polymeric material. One example of this type of arrangement would be a braid lined with a Teflon polymer. - Because the ekoskeleton might remain permanently in the vasculature, it may be desirable to promote tissue growth (e.g., cellular encapsulation, in-growth, endothelialization) onto and/or into the
exoskeleton 13 a. Tissue growth onto/into the exoskeleton can improve the stability of the exoskeleton within the vessel, and may improve the biocompatibility of the system within the vessel by improving blood-surface compatibility. Cellular growth may be encouraged by giving the exoskeleton an in-growth promoting surface using structural features. For example, all or a portion of the exterior surface of the exoskeleton may have pores (e.g., from a porous material), interstices (e.g., in a mesh material), or other surface modifications into or onto which cellular growth can occur. In one embodiment, the exoskeleton may have an exterior surface formed or covered by Dacron or by a form of ePTFE having a node to fibril length of approximately 15-25 microns. Cellular growth into or onto the exoskeleton may also be promoted using a substance that promotes in-growth. For example, the exoskeleton may be coated or impregnated with a substance such as albumen, growth factors, synthetic or natural therapeutic molecules, or any other substance that will promote cellular growth. - On the other hand, if the option to explant the exoskeleton is desired, it may be formed of a material or covered by a layer or coating having anti-proliferative properties so as to minimize endothelialization or cellular ingrowth, since minimizing growth into or onto the device will help minimize vascular trauma when the device is explanted. A form of ePTFE having a note-to-fibril length of approximately 1-10 microns, and preferably less than approximately 10 microns, may be used for this purpose.
- In another embodiment, the exoskeleton may be constructed such that it will degrade over a period of time calculated such that degradation will occur after the intended useful life of the insert. Materials suitable for this purpose include LPLA, polyglycolic acid, polydioxanone, polyanhydrides or other erodable materials. According to this embodiment, degradation of the exoskeleton would preferably be timed to occur following removal of the implant.
- The exoskeleton surface may also be anti-thrombogenic (e.g., using materials or coating such as perfluorocarbon coatings applied using supercritical carbon dioxide), although if cellular ingrowth is desired some thrombosis may be allowed as a substrate for endothelial growth. The exoskeleton may also include a surface or coating, which elutes compositions, such as anti-thrombogenic compositions (e.g., heparin sulfate) and/or anti-proliferative compositions and/or immunosuppressive agents.
- Referring to
FIG. 2 , the most proximal section of the device may include atransition 17 a to a moreflexible tail section 17 b of the exoskeleton, which may be coiled and tucked into a subcutaneous pocket following implantation as will be discussed below. - In another embodiment, the
insert 13 b may fit snugly into theexoskeleton 13 a, in which case the exoskeleton may function as a coating on theinsert 13 b. - One or more electrode leads 14 may extend as branches from the
exoskeleton 13 a. Leads includeelectrodes 16 for delivering electrical energy to the surrounding body tissue. In theFIG. 2 embodiment, thelead 14 may be positionable with in the right ventricle (RV) of the heart. Additional electrodes may be positioned on the body of the exoskeleton. For example, the exoskeleton may includeelectrodes 18 a positionable within the left subclavian vein (LSV) 2 b, andelectrodes 18 b positionable within the inferior vena cava (IV C) 3 b. - It should be noted that the term “exoskeleton” is not intended to mean that the
exoskeleton 13 a is necessarily hard or rigid. As discussed, the exoskeleton preferably forms a barrier against migration of body fluids into contact with the insert, but it need not be a rigid barrier. In a preferred embodiment the exoskeleton is sufficiently flexible to be passed through the vasculature. However, certain sections of theexoskeleton 13 a may include additional features that supplement the strength and stability of those sections after they have been positioned at their final location within the vasculature. This may be desirable during removal of theinsert 13 b from theexoskeleton 13 a to assist theexoskeleton 13 a in resisting axial forces applied against it during withdrawal of the insert. - For example, in the
FIG. 2 embodiment it may be desirable to reinforce thelead 14 or the portion of the exoskeleton positioned distally oflead bifurcation 11. One reinforcement method might include providing the exoskeleton with pockets of curable or reactive polymer in a liquid state. These pockets might be positioned throughout the exoskeleton, or at select regions such as thelead 14, and/or thebifurcation 11, and points distal to thebifurcation 11. Once the exoskeleton is positioned or just prior to extraction of the insert, the polymer would be cured using the appropriate curing method (e.g., UV exposure, chemical contact, thermal activation, etc.). The cured material can help the exoskeleton to retain a desired shape within the vessel, and can assist with axial stability. Another embodiment of a reinforcement method might involve inserting reinforcing wires or ribbons through lumens in the sidewalls of the exoskeleton following implantation of the exoskeleton or just prior to extraction of the insert. - Referring to
FIG. 3A , the interior surface of the exoskeleton includes a plurality ofelectrical contacts 19 a, b, c. Each of thecontacts corresponding wire electrode arrays FIG. 3A also illustrates an alternative form of electrodes that differ from the surface electrodes shown on theFIG. 2 embodiment. In theFIG. 3A embodiment, each wire (e.g.,wire 20 a) extending through the exoskeleton penetrates the wall of the exoskeleton and is wound on the surface of the exoskeleton to form the electrode. Sealing compound is preferably used to seal the exoskeleton at the point of penetration. - Referring again to
FIG. 2 , theinsert 13 b is a hermetically sealed housing containing electronics and other features necessary for the operation of the system. These features may include one or more pulse generators, including associated batteries, capacitors, microprocessors, and circuitry for generating defibrillation pulses. Detection circuitry for detecting arrhythmias or other abnormal activity of the heart may also be housed withininsert 13 b. The housing may be made from metals such as titanium or titanium alloys, polymers, or other suitable materials. Although the exoskeleton will preferably isolate the insert from body materials, the insert may be covered by a layer or coating having anti-proliferative properties so as to minimize endothelialization or cellular ingrowth onto the insert in the event some fluids migrate into the exoskeleton. - One or more
electrical contacts insert 13 b. Thecontacts insert 13 b includes a conductive housing to which an insulating material is to be applied, the contacts may be formed by selectively applying the coating or removing portions of the coating to leave one or more exposed contact regions on the surface of the insert. -
Contacts contacts FIG. 3A ) inside the exoskeleton when thedevice 12 is fully assembled. When the contacts are properly coupled, electrical energy emitted by the pulse generator within the housing is directed to theappropriate electrodes insert 13 b. -
FIG. 3B illustrates alternative positioning of thecontacts 19 a, b, c and thecontacts device 12 as shown inFIG. 3A , theFIG. 3B embodiment positionscontacts LSV electrode 18 a, andcontacts IVC electrode 18 b. Thecontacts RV electrode 16 are positioned near the bifurcation of thelead 14. - Returning again to
FIG. 3A , it should be noted that if thecontacts 19 a, b, c are positioned in a proximal portion of theexoskeleton 13 a, theinsert 13 b need not be proportioned to extend to the distal end of the exoskeleton. However, theinsert 13 b may be long enough to extend to the distal end even if it not necessary for making electrical contact. - Another arrangement of contacts is shown in
FIG. 3C , which illustrates the distal portion ofinsert 13 b disposed within the distal portion ofexoskeleton 13 b. The walls of the exoskeleton are shown in cross-section to allow the insert to be seen. As shown, a tiered structure is used for the distal portions of the insert and exoskeleton with conductiverings forming contacts tier 7 aconductive ring 19 e lines the interior surface of theexoskeleton 13 b, and a correspondingconductive ring 22 e lines the exterior surface of theinsert 13 a. The tiers may be proportioned such to create an interference fit between the insert and the exoskeleton. - The system may include alternative features that engage the
insert 13 b within theexoskeleton 13 a. The retention forces between the exoskeleton and insert are preferably sufficient to retain the insert, but also such that they may be overcome by manually withdrawing theinsert 13 b. As one example, the interior surface of the exoskeleton and/or the exterior surface of the insert may include raised elements (e.g., rib features, broadened sections etc.) that cause the two components to engage due to friction forces between adjacent surfaces.FIG. 4A illustrates raisedelements 23 on the surface of theinsert 13 b. Alternatively, the general fit between thecomponents - As another example, one or more of the contacts within the
exoskeleton 13 a may take the form of a metallic leaf spring radially biased towards the central axis of the exoskeleton. This is illustrated inFIG. 4B . In this embodiment, thecontacts 19 b are inwardly biased leaf springs. Theelectrodes 18 a may be strips of conductive material or sections of conductive tubing electrically coupled to thecontacts 22b using rivets 21 or other conductive elements passing through the wall of the exoskeleton. As shown, when the insert is placed within the exoskeleton,leaf spring contact 19 b springs into engagement with acorresponding contact 22 b on theinsert 13 b. To facilitate engagement, thecontact 22 b may be positioned within a recess formed in the surface of theinsert 13 b as shown. A plurality of similar leaf springs (which may or may not be conductive) may be used at one or more locations on the exoskeleton surface to ensure that engagement between the components is secure. - Some alternative electrode and contact designs similar to the
FIG. 3A design are shown inFIGS. 10A and 10B . It should be mentioned that the configurations for the electrodes and associated contacts described in this application are merely examples and not given as an all-inclusive list. - In one embodiment shown in
FIG. 10A , anelectrode 18 d comprises a wire coil, wherein a first portion of the coil is positioned within the exoskeleton to form acontact 19 d that makes contact with a corresponding contact on the insert. A second portion of the coil is wrapped around the exterior surface of the exoskeleton for contact with tissue. - In a similar embodiments shown in
FIG. 10B , theelectrode 18 e is formed of a strand wire wound in an undulating pattern. A portion of the pattern is positioned inside the exoskeleton to serve ascontact 19 e, whereas another portion extends through the exoskeleton wall to form the external electrode. A similar pattern may be cut into a sheet or tube of metal rather than looped using a wire. Thecontact portion 19 e of the wire may be biased inwardly in a manner similar to theleaf springs 19 b ofFIG. 4B - Referring again to
FIG. 2 , one or more retention devices such asanchor 24 are provided for retaining the exoskeleton within a blood vessel.Anchor 24 includes structural features that allow the anchor to self-expand into radial engagement with a vessel wall. For example, a band, mesh or other framework formed of one or more shape memory (e.g., nickel titanium alloy, nitinol, thermally activated shape-memory material, or shape memory polymer) elements or stainless steel, Elgiloy, or MP35N elements may be used. In this embodiment theanchor 24 is preferably constructed to promote tissue ingrowth to as to enhance anchor stability within the vessel. Structural features such as mesh or other framework configurations are suitable for this purpose, although compositions and/or coatings that promote in-growth may also be used. - During implantation, a
retractable sheath 26 may be slidably positioned over theanchor 24 and theexoskeleton 13 a so as to retain the anchor in its compressed position. (Thesheath 26 may also be used to hold thelead branch 14 streamlined against theexoskeleton 13 a during implantation.) Retraction of the sheath once the exoskeleton is properly positioned allows theanchor 24 to expand into contact with the surrounding walls of the vessel, thereby holding the exoskeleton in the desired location. Once deployed, theanchor 24 is preferably intimate to the vessel wall, which is distended slightly, allowing the vessel lumen to remain approximately continuous despite the presence of the anchor and thus minimizing turbulence or flow obstruction. Although self-expansion of the anchor is preferable, mechanical expansion means (e.g., balloon expanders etc) may be used for active expansion of the anchor. - The anchor may also have drug delivery capability via a coating matrix impregnated with one or more pharmaceutical agents.
- The
anchor 24 may be configured such that theexoskeleton 13 a andanchor 24 share a longitudinal axis, or such that the axes of theexoskeleton 13 a andanchor 24 are longitudinally offset. - An
implantation mandrel 28 is attachable to the proximal end ofexoskeleton 13 a (e.g., attransition region 17 a) for advancing the exoskeleton into position within the body. Themandrel 28 may also be used to push the insert into the exoskeleton or a separate tool can be used for this purpose. The system may additionally be provided with other components useful for implanting the system, includingguidewires introducer 32. If guidewires are to be used for implantation of the exoskeleton, the exoskeleton will preferably include guidewire lumens that permit tracking of the exoskeleton over the guidewires, or openings formed at the distal end of the exoskeleton and/or lead 14 for receiving the guidewires. The distal openings would preferably include seals to prevent migration of blood or other body fluids into the exoskeleton. The openings might instead include one-way valves that allow any body fluids that pass into the exoskeleton to be purged from the exoskeleton using a fluid (e.g., saline or carbon dioxide gas) injected into the proximal opening 15. -
FIGS. 5A through 5E illustrate implantation of thesystem 10 ofFIG. 2 . In the illustrated method, the exoskeleton is implanted first, and then the insert is passed into the exoskeleton. However, in an alternative implantation method the insert may be passed into the exoskeleton outside the body and the two components introduced simultaneously. - A small incision is first formed in the femoral vein and the
introducer sheath 32 is inserted through the incision into the vein to keep the incision open during the procedure. Next, guidewires 30 a, 30 b are passed through thesheath 32 and into theinferior vena cava 3 b.Guidewire 30 a is steered under fluoroscopy into the leftsubclavian vein 2 b and guidewire 30 b is guided into theright ventricle 7 a of the heart. In an alternative embodiment of the implantation, only guidewire 30 b is used and is advanced into theright ventricle 7 a. - Next, the lead 14 (
FIG. 2 ) is threaded overguidewire 30 b by extending the guidewire into the exoskeleton and out of the exoskeleton via an opening in thelead 14. If both guidewires are used, the distal end of theexoskeleton 3 b is threaded overguidewire 30 a. Thelead 14 and the distal end of theexoskeleton 13 a are then passed through theintroducer sheath 32 and into theIVC 3 b. SeeFIG. 5A . Pushing on the exoskeleton causes thelead 14 to track overguidewire 30 b while the exoskeleton advances within the vasculature (and overguidewire 30 b if used). - The
guidewires - Next,
implantation mandrel 28 is attached to the proximal portion of theexoskeleton 13 a (e.g., attransition region 17 a) and is used to push the exoskeleton further into the vasculature. Advancement of themandrel 28 is continued until the distal portion of the exoskeleton reaches the desired position within theLSV 2 b, and thelead 14 had tracked theguidewire 30 b into theright ventricle 7 a as shown inFIG. 5B . At this stage, some of theflexible tail section 17 b of the exoskeleton remains outside the body. - The exoskeleton is next anchored in place by releasing the
anchor 24 to its expanded position as shown inFIG. 5C . The anchor expands into contact with the surrounding vessel wall, thereby preventing migration of the exoskeleton. If desired, the distal portion ofexoskeleton 13 a may be anchored in theLSV 2 b using another suitable anchor. Themandrel 28 is detached from the exoskeleton and withdrawn from the body. - Next, the
insert 13 b is inserted into the exoskeleton as shown inFIG. 5D . If necessary, theimplantation mandrel 28 may be attached to theinsert 13 b and used to push theinsert 13 b into position. Theinsert 13 b is advanced to a point at which the contacts on theinsert 13 b have made electrical contact with the corresponding contacts of the exoskeleton. Finally, themandrel 28 is removed and theopening 15 a in exoskeleton is sealed using a cap or plug 15 b, or using a sealing compound that will harden to seal theopening 15 a. Theflexible tail section 17 b of the exoskeleton is coiled and tucked into the femoral vein or into a subcutaneous pocket adjacent to the femoral vein and is stored there for future access. The incision through the patient's skin is preferably closed and allowed to heal. - Future access to the
insert 13 b may be needed for a variety of reasons. For example, if the battery within theinsert 13 b should become depleted, the insert may be removed and replaced with a new device, or a charging device may be coupled to theinsert 13 b. - If the insert is to be replaced, a femoral incision is formed to gain access to the
tail section 17 b. A sufficient length of thetail 17 b is removed from the body to permit access to theopening 15 a in thetail 17 b. The opening 15 a is unsealed such as by removing its cap, plug 15 b or seal. Alternatively, the exoskeleton may be re-opened by snipping off the proximal portion of the tail within which the cap, plug or seal is positioned. An extraction tool such asmandrel 28 may be passed into the exoskeleton and used to engage the insert. To facilitate this process, an alternative mandrel may be used that includes a distal coupling comprising a mouth that is significantly broader than the proximal end of the device. When the mandrel is advanced through the exoskeleton towards theinsert 13 b, the mouth will pass over the proximal end of thedevice 10 and will then be actuated to clamp over the proximal end of the insert, allowing the insert to be withdrawn by retracting the mandrel from within thetail section 17 b. Once the insert is extracted, a fresh insert may be advanced into the exoskeleton using techniques described above, and the tail may be re-sealed and returned to its pocket within the body. - An alternative extraction method is illustrated in
FIG. 5F . As shown, asyringe 60 may be coupled to theexoskeleton 13 a and used to pump saline, carbon dioxide, or other fluid into the exoskeleton. As the injected fluid fills the distal portion of the exoskeleton, fluid pressure forces the insert towards the open end of the exoskeleton. This step may also be combined with manual extraction using a mandrel. Once the insert is extracted, a fresh component may be inserted into the exoskeleton and will displace any fluid remaining in the exoskeleton will be driven out the opening 15 a by the advancing insert. -
FIG. 6 shows an alternative embodiment of a system 110 utilizing anexoskeleton 113 a and aninsert 113 b insertable into the exoskeleton. In system 110, leads 14 a, 14 b extend from theexoskeleton 113 a as shown. Each lead 114 a, 114 b is electrically connected to a contact point (not shown) that is exposed in the hollow interior of theexoskeleton 113 a. The contact points are positioned to make electrical contact withcorresponding points 122 on the surface of the interior housing when theexoskeleton 113 a and insert 113 b are assembled. - The exoskeleton and the
insert FIG. 6 , threaded female andmale connectors insert 13 b into theexoskeleton 13 a, theinsert 113 a is rotated to engage the threads of the connectors. Additional sealing structures (e.g., o-rings) may be included on the proximal end of one or both of thecomponents FIG. 7 ,threads 42 a may be formed on the exterior surface near the distal end of theinsert 113 b, with corresponding female threads on the exoskeleton (not shown). In either case, an implantation tool (which may be similar tomandrel 28 ofFIG. 2 ) would be connectable to theinsert 113 b and used for guiding theinsert 113 b through the vasculature and then rotating thecomponent 113 b to cause the corresponding threads to engage. - As yet another alternative, as shown in
FIGS. 8A and 8B , insert 113 b (FIG. 8B ) may include aspring clip 44, andexoskeleton 113 a (FIG. 8A ) may include awindow 46, such that when the components are assembled theclip 44 engages with the window as shown inFIG. 8C . Sinceclip 44 may be exposed through thewindow 46, it may be desirable to wire theclip 44 to function as an electrode on the exterior of the device. - As discussed, one or more o-ring seals 50 (
FIGS. 7, 8A and 8C) may be used to keep fluids out of the exoskeleton. Seals (not shown) may also be used around theclip 44 to prevent fluid leakage from entering thedevice 112 through the window. - In another alternative embodiment shown in
FIG. 9 , leads 214 are attached to theinsert 213 b, and the exoskeleton 214 a includes openings through which the leads may be passed during implantation. In theFIG. 9 embodiment exoskeleton 213 a includessleeves 52 through which the leads may be passed for this purpose. Alternatively, the exoskeleton may include holes in the distal end in place ofsleeves 52. Seals (such as o-rings of the type discussed earlier) may be positioned to prevent migration of fluids into the exoskeleton via thesleeves 52. - During implantation of the
system 212, leads 214 are fed through thesleeves 52 and are positioned within the heart and/or vessels in a manner similar to that described above. Fluid such as saline or gas such as carbon dioxide may be directed into the open proximal end of the exoskeleton to prevent inflow of blood or to displace blood that may have already have entered the exoskeleton during implantation. Holes or one-way valves (not shown) may also be formed in the distal region of the exoskeleton to allow any blood that may have accumulated within the exoskeleton to be displaced and evacuated as the insert is passed into the exoskeleton to facilitate retention in the body. - Drug Delivery System
- The exoskeleton configuration may be adapted for use with an intravascular drug delivery system of the type describe in U.S. application Ser. No. ______, INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS, filed Dec. 9, 2004, Attorney Docket No. NMX-110, which is incorporated herein by reference. Such a system includes an implantable drug reservoir, together with components that function to transfer drug from the reservoir into the bloodstream or into certain organs or tissues. Components used for this purpose may include pumps, motors and batteries, and/or other components such as those listed in the NMX-110 application.
- Referring to
FIG. 11 , asystem 310 may include anexoskeleton 313 a and aninsert 313 b slidably received within theexoskeleton 313 a.Insert 313 b includes adrug reservoir 314 and arefill line 318 coupled to the reservoir. Apump system 316 directs agent to an exit tube ororifice 320. - Exoskeleton includes a
port 322 that allows fluid released through theexit orifice 320 to pass into the bloodstream. Aseal 324 may be positioned within the exoskeleton to prevent backflow of drug fromexit orifice 320 into theexoskeleton 313 a. - The exoskeleton may include a
flexible tail portion 317 that, as described in connection with theFIG. 2 embodiment, may be tucked into the femoral vein or a subcutaneous pocket following implantation. - A
subcutaneous portal 326 is fluidly coupled to therefill line 318 of reservoir, and may also function to seal thetail 317 of the exoskeleton.Portal 326 may include a one-way valve (not shown) that prevents fluid from entering the exoskeleton, or it may include a seal formed of a material that will reseal itself following puncture. - Implantation of the
system 310 and replacement of theinsert 313 b may be performed using techniques described above. Thereservoir 314 may be refilled by using a refill vessel such as arecharge syringe 328 filled with the desired drug. The needle tip of the recharge syringe may be inserted through the skin and into thesubcutaneous portal 326. In this embodiment, drug reservoir within theinsert 313 b may be maintained at a negative pressure so as to draw the agent from the syringe once fluid communication is established. Thus provides feedback to the user that the syringe needle has been inserted at the proper location and can thus help to avoid injection of the agent directly into the patient in the event the portal 326 is missed by the needle. - In an alternative refill method, the
tail 317 may be withdrawn from the body through a small incision, and therecharge syringe 328 or other refill device may be coupled to the portal 326 outside the body. In either case, the drug is then injected from the syringe into the reservoir via the portal 326 andrefill line 318. If thesystem 310 is provided without a refill line and portal, the insert may instead be replaced with a new component containing a fresh supply of drug using methods described above. - In another embodiment, the
insert 313 b may be provided with a refill port in theinsert body 313 b rather than afill line 318 extending from the insert. Such an embodiment might be refilled using a mandrel having a distal coupling including a mouth that is significantly broader than the proximal end of the device. To refill a device according to this embodiment, the mandrel would be introduced into the exoskeleton and advanced towards the insert until it passes over the proximal end of the insert. The mandrel is then clamped over the proximal end of the insert to sealingly engage the insert and to create a fluid coupling between the mandrel's fluid lumen and a refill lumen into the insert. Drug is then introduced into the mandrel for delivery into the reservoir within the insert. - Various embodiments of systems, devices and methods have been described herein. These embodiments are given only by way of example and are not intended to limit the scope of the present invention. The examples and alternatives set forth for the described components are merely examples and should not be considered to be all-inclusive lists. It should be appreciated, moreover, that the various features of the embodiments that have been described might be combined in various ways to produce numerous additional embodiments. Moreover, while various materials, dimensions, shapes, implantation locations, etc. have been described for use with disclosed embodiments, others besides those disclosed may be utilized without exceeding the scope of the invention.
Claims (23)
1. A method of implanting a medical device within a living body, the method comprising the steps of:
forming an incision in a living body;
introducing a sleeve having a length through the incision;
positioning the entire length of the sleeve within the body;
inserting an implantable medical device into the sleeve and sealing the medical device within the sleeve.
2. The method of claim 1 , wherein the positioning step positions at least a portion of the sleeve within a blood vessel.
3. The method of claim 1 , wherein the inserting step is performed prior to the introducing step.
4. The method of claim 1 , wherein the inserting step is performed after the introducing step.
5. The method of claim 2 , further including the step of anchoring the sleeve within the blood vessel.
6. The method of claim 5 , wherein the sleeve includes an expandable retention device, and wherein the anchoring step includes the step expanding the retention device into contact with walls of the vessel.
7. The method of claim 2 , wherein the positioning step positions the entire length of the sleeve within the blood vessel.
8. The method of claim 1 , wherein the medical device is removable from the sleeve while the sleeve remains within the body.
9. The method of claim 1 , wherein the sealing step attaches a sealing device to the sleeve.
10. The method of claim 9 , wherein the sealing step attaches a cap or plug to the sleeve.
11. The method of claim 9 , wherein the sealing step applies a sealing compound to the sleeve.
12. The method of claim 1 , wherein after the sealing step, the sleeve substantially prevents body fluids surrounding the sleeve from contacting the medical device.
13. The method of claim 1 , wherein after the sealing step, the sleeve substantially prevents biological growth onto the medical device.
14. The method of claim 1 , wherein
the introducing step introduces a sleeve having an exterior and at least one electrode on the exterior;
the sealing inserting step inserts a medical device having an interior and pulse generator sealed within the interior; and
the method further includes the step of electrically coupling the pulse generator to the electrode.
15. The method of claim 14 , wherein the sleeve includes a side branch extending from the sleeve, wherein the method includes positioning the side branch within the heart.
16. The method of claim 15 , wherein at least one electrode is a branch electrode positioned on the side branch, and wherein the electrically coupling step couples the branch electrode to the pulse generator.
17. The method of claim 1 , wherein:
the introducing step introduces a sleeve having a fluid delivery port;
the inserting step inserts a medical device having an interior and a fluid reservoir in the interior; and
the method further includes the step of fluidly coupling the fluid delivery port and the fluid reservoir.
18. The method of claim 1 , wherein the method is further for explanting the medical device, and wherein the method includes the steps of:
withdrawing a portion of the sleeve from the body; and
extracting the medical device from within the sheath.
19. The method of claim 18 , further including the step of:
after the extracting step, inserting a second medical device into the sleeve.
20. The method of claim 1 , further include the step of allowing the incision to heal, leaving the medical device and the sleeve within the body.
21-40. (canceled)
41. An implantable intravascular medical system kit, including:
a elongate sleeve proportioned for implantation within a blood vessel of a patient;
an implantable medical device positionable within the sleeve; and
instructions for use setting forth implantation methods for the sleeve and medical device, including the steps of:
forming an incision in a living body;
introducing the sleeve through the incision and into a blood vessel;
positioning an entire length of the sleeve within the body;
inserting the medical device into the sleeve and sealing the medical device within the sleeve.
42-43. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/981,008 US20080058886A1 (en) | 2003-12-12 | 2007-10-31 | Implantable medical device having pre-implant exoskeleton |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52905103P | 2003-12-12 | 2003-12-12 | |
US11/009,649 US7747335B2 (en) | 2003-12-12 | 2004-12-10 | Implantable medical device having pre-implant exoskeleton |
US11/981,008 US20080058886A1 (en) | 2003-12-12 | 2007-10-31 | Implantable medical device having pre-implant exoskeleton |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/009,649 Division US7747335B2 (en) | 2003-12-12 | 2004-12-10 | Implantable medical device having pre-implant exoskeleton |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080058886A1 true US20080058886A1 (en) | 2008-03-06 |
Family
ID=34699932
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/009,649 Expired - Fee Related US7747335B2 (en) | 2003-12-12 | 2004-12-10 | Implantable medical device having pre-implant exoskeleton |
US11/981,363 Abandoned US20080065051A1 (en) | 2003-12-12 | 2007-10-31 | Implantable medical device having pre-implant exoskeleton |
US11/981,008 Abandoned US20080058886A1 (en) | 2003-12-12 | 2007-10-31 | Implantable medical device having pre-implant exoskeleton |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/009,649 Expired - Fee Related US7747335B2 (en) | 2003-12-12 | 2004-12-10 | Implantable medical device having pre-implant exoskeleton |
US11/981,363 Abandoned US20080065051A1 (en) | 2003-12-12 | 2007-10-31 | Implantable medical device having pre-implant exoskeleton |
Country Status (6)
Country | Link |
---|---|
US (3) | US7747335B2 (en) |
EP (1) | EP1701766A2 (en) |
JP (1) | JP2007514482A (en) |
AU (1) | AU2004298995A1 (en) |
CA (1) | CA2549006A1 (en) |
WO (1) | WO2005058415A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040249431A1 (en) * | 2003-06-04 | 2004-12-09 | Terrance Ransbury | Device and method for retaining a medical device within a vessel |
US20050154437A1 (en) * | 2003-12-12 | 2005-07-14 | Williams Michael S. | Implantable medical device having pre-implant exoskeleton |
US20070265673A1 (en) * | 2006-04-03 | 2007-11-15 | Terrance Ransbury | Flexible interconnect assembly for implantable medical devices |
US20080167702A1 (en) * | 2006-12-04 | 2008-07-10 | Terrance Ransbury | Intravascular implantable device having superior anchoring arrangement |
US20090281521A1 (en) * | 2003-06-04 | 2009-11-12 | Williams Michael S | Method and apparatus for retaining medical implants within body vessels |
US20100318166A1 (en) * | 2009-06-12 | 2010-12-16 | Terrance Ransbury | Methods and systems for anti-thrombotic intravascular implantable devices |
US20160023003A1 (en) * | 2012-07-17 | 2016-01-28 | Laura Tyler Perryman | Miniature implantable device and methods |
US9289612B1 (en) | 2014-12-11 | 2016-03-22 | Medtronic Inc. | Coordination of ventricular pacing in a leadless pacing system |
US9399140B2 (en) | 2014-07-25 | 2016-07-26 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
US9492668B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9492669B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9623234B2 (en) | 2014-11-11 | 2017-04-18 | Medtronic, Inc. | Leadless pacing device implantation |
US9724519B2 (en) | 2014-11-11 | 2017-08-08 | Medtronic, Inc. | Ventricular leadless pacing device mode switching |
US10390720B2 (en) | 2014-07-17 | 2019-08-27 | Medtronic, Inc. | Leadless pacing system including sensing extension |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7529589B2 (en) * | 2003-06-04 | 2009-05-05 | Synecor Llc | Intravascular electrophysiological system and methods |
US8116883B2 (en) * | 2003-06-04 | 2012-02-14 | Synecor Llc | Intravascular device for neuromodulation |
US8340779B2 (en) | 2003-08-29 | 2012-12-25 | Medtronic, Inc. | Percutaneous flat lead introducer |
US20050142315A1 (en) * | 2003-12-24 | 2005-06-30 | Desimone Joseph M. | Liquid perfluoropolymers and medical applications incorporating same |
US20050273146A1 (en) * | 2003-12-24 | 2005-12-08 | Synecor, Llc | Liquid perfluoropolymers and medical applications incorporating same |
US20120277839A1 (en) | 2004-09-08 | 2012-11-01 | Kramer Jeffery M | Selective stimulation to modulate the sympathetic nervous system |
US8082039B2 (en) | 2004-09-08 | 2011-12-20 | Spinal Modulation, Inc. | Stimulation systems |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
US7792591B2 (en) * | 2005-06-09 | 2010-09-07 | Medtronic, Inc. | Introducer for therapy delivery elements |
WO2007059386A2 (en) * | 2005-11-10 | 2007-05-24 | Medtronic, Inc. | Intravascular medical device |
US7519424B2 (en) | 2006-01-30 | 2009-04-14 | Medtronic, Inc. | Intravascular medical device |
US7616992B2 (en) | 2006-01-30 | 2009-11-10 | Medtronic, Inc. | Intravascular medical device |
US7627376B2 (en) * | 2006-01-30 | 2009-12-01 | Medtronic, Inc. | Intravascular medical device |
US20080147168A1 (en) * | 2006-12-04 | 2008-06-19 | Terrance Ransbury | Intravascular implantable device having detachable tether arrangement |
EP2094352A4 (en) | 2006-12-06 | 2010-05-19 | Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
WO2008070808A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Expandable stimulation leads and methods of use |
WO2008070809A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
WO2008070807A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
US8709631B1 (en) * | 2006-12-22 | 2014-04-29 | Pacesetter, Inc. | Bioelectric battery for implantable device applications |
US8388670B1 (en) | 2007-01-16 | 2013-03-05 | Pacesetter, Inc. | Sensor/lead systems for use with implantable medical devices |
US8103359B2 (en) * | 2007-05-17 | 2012-01-24 | Cardiac Pacemakers, Inc. | Systems and methods for fixating transvenously implanted medical devices |
CN101932283B (en) * | 2007-12-03 | 2013-06-19 | 内脉冲公司 | Implantation methods, systems and tools for intravascular implantable devices |
US20090192579A1 (en) * | 2007-12-03 | 2009-07-30 | Terrance Ransbury | Implantation methods, systems and tools for intravascular implantable devices |
US20090198251A1 (en) * | 2008-02-06 | 2009-08-06 | Terrance Ransbury | Lead delivery, fixation and extraction devices and methods for use with intravascular implantable medical devices |
US7925352B2 (en) | 2008-03-27 | 2011-04-12 | Synecor Llc | System and method for transvascularly stimulating contents of the carotid sheath |
US20100211131A1 (en) * | 2008-04-07 | 2010-08-19 | Williams Michael S | Intravascular system and method for blood pressure control |
US8239037B2 (en) * | 2008-07-06 | 2012-08-07 | Synecor Llc | Intravascular implant anchors having remote communication and/or battery recharging capabilities |
CN102202729B (en) | 2008-10-27 | 2014-11-05 | 脊髓调制公司 | Selective stimulation systems and signal parameters for medical conditions |
CN102438698B (en) | 2009-03-24 | 2014-09-10 | 脊髓调制公司 | Pain management with stimulation subthreshold to parasthesia |
US9173760B2 (en) | 2009-04-03 | 2015-11-03 | Metamodix, Inc. | Delivery devices and methods for gastrointestinal implants |
US9278019B2 (en) | 2009-04-03 | 2016-03-08 | Metamodix, Inc | Anchors and methods for intestinal bypass sleeves |
CN102387762B (en) | 2009-04-03 | 2014-08-06 | 美特默迪克斯公司 | Modular gastrointestinal prostheses |
WO2010132816A2 (en) | 2009-05-15 | 2010-11-18 | Spinal Modulation, Inc. | Methods, systems and devices for neuromodulating spinal anatomy |
US20110004288A1 (en) * | 2009-06-12 | 2011-01-06 | Terrance Ransbury | Intravascular implantable device having integrated anchor mechanism |
IN2012DN00316A (en) | 2009-07-10 | 2015-05-08 | Metamodix Inc | |
US9327110B2 (en) | 2009-10-27 | 2016-05-03 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Devices, systems and methods for the targeted treatment of movement disorders |
US20130331921A1 (en) * | 2012-06-08 | 2013-12-12 | Gary Roubin | Bifurcated catheter |
US9623253B2 (en) | 2012-07-17 | 2017-04-18 | Micron Devices, LLC | Devices and methods for treating urological disorders |
AU2013355223B2 (en) * | 2012-12-05 | 2018-05-17 | Curonix Llc | Devices and methods for connecting implantable devices to wireless energy |
US10159699B2 (en) | 2013-01-15 | 2018-12-25 | Metamodix, Inc. | System and method for affecting intestinal microbial flora |
ES2661718T3 (en) | 2014-01-10 | 2018-04-03 | Cardiac Pacemakers, Inc. | Methods and systems to improve communication between medical devices |
AU2015204701B2 (en) | 2014-01-10 | 2018-03-15 | Cardiac Pacemakers, Inc. | Systems and methods for detecting cardiac arrhythmias |
CN111790047B (en) * | 2014-05-22 | 2022-09-27 | 卡迪诺米克公司 | Catheter and catheter system for electrical neuromodulation |
WO2016033197A2 (en) | 2014-08-28 | 2016-03-03 | Cardiac Pacemakers, Inc. | Medical device with triggered blanking period |
WO2016040037A1 (en) | 2014-09-08 | 2016-03-17 | CARDIONOMIC, Inc. | Catheter and electrode systems for electrical neuromodulation |
EP3194017A1 (en) | 2014-09-08 | 2017-07-26 | Cardionomic, Inc. | Methods for electrical neuromodulation of the heart |
US10376618B2 (en) | 2014-10-29 | 2019-08-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thoracic catheter device |
WO2016111940A1 (en) | 2015-01-05 | 2016-07-14 | CARDIONOMIC, Inc. | Cardiac modulation facilitation methods and systems |
US10220213B2 (en) | 2015-02-06 | 2019-03-05 | Cardiac Pacemakers, Inc. | Systems and methods for safe delivery of electrical stimulation therapy |
US9669230B2 (en) | 2015-02-06 | 2017-06-06 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
WO2016130477A2 (en) | 2015-02-09 | 2016-08-18 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque id tag |
WO2016141046A1 (en) | 2015-03-04 | 2016-09-09 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US10213610B2 (en) | 2015-03-18 | 2019-02-26 | Cardiac Pacemakers, Inc. | Communications in a medical device system with link quality assessment |
US10050700B2 (en) | 2015-03-18 | 2018-08-14 | Cardiac Pacemakers, Inc. | Communications in a medical device system with temporal optimization |
EP3103508A1 (en) * | 2015-06-11 | 2016-12-14 | Micron Devices, LLC | Embedded fixation devices or leads |
CN108136187B (en) | 2015-08-20 | 2021-06-29 | 心脏起搏器股份公司 | System and method for communication between medical devices |
CN108136186B (en) | 2015-08-20 | 2021-09-17 | 心脏起搏器股份公司 | System and method for communication between medical devices |
US9968787B2 (en) | 2015-08-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Spatial configuration of a motion sensor in an implantable medical device |
US9956414B2 (en) | 2015-08-27 | 2018-05-01 | Cardiac Pacemakers, Inc. | Temporal configuration of a motion sensor in an implantable medical device |
US10226631B2 (en) | 2015-08-28 | 2019-03-12 | Cardiac Pacemakers, Inc. | Systems and methods for infarct detection |
WO2017040115A1 (en) | 2015-08-28 | 2017-03-09 | Cardiac Pacemakers, Inc. | System for detecting tamponade |
CN108136189B (en) | 2015-08-28 | 2021-10-15 | 心脏起搏器股份公司 | System for behavioral response signal detection and therapy delivery |
WO2017044389A1 (en) | 2015-09-11 | 2017-03-16 | Cardiac Pacemakers, Inc. | Arrhythmia detection and confirmation |
US10065041B2 (en) | 2015-10-08 | 2018-09-04 | Cardiac Pacemakers, Inc. | Devices and methods for adjusting pacing rates in an implantable medical device |
JP6608063B2 (en) | 2015-12-17 | 2019-11-20 | カーディアック ペースメイカーズ, インコーポレイテッド | Implantable medical device |
US10905886B2 (en) | 2015-12-28 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device for deployment across the atrioventricular septum |
US10583303B2 (en) | 2016-01-19 | 2020-03-10 | Cardiac Pacemakers, Inc. | Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device |
WO2017136548A1 (en) | 2016-02-04 | 2017-08-10 | Cardiac Pacemakers, Inc. | Delivery system with force sensor for leadless cardiac device |
US9622897B1 (en) | 2016-03-03 | 2017-04-18 | Metamodix, Inc. | Pyloric anchors and methods for intestinal bypass sleeves |
AU2017229496B2 (en) | 2016-03-09 | 2022-03-31 | CARDIONOMIC, Inc. | Cardiac contractility neurostimulation systems and methods |
CN108883286B (en) | 2016-03-31 | 2021-12-07 | 心脏起搏器股份公司 | Implantable medical device with rechargeable battery |
US10328272B2 (en) | 2016-05-10 | 2019-06-25 | Cardiac Pacemakers, Inc. | Retrievability for implantable medical devices |
US10668294B2 (en) | 2016-05-10 | 2020-06-02 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker configured for over the wire delivery |
KR102473258B1 (en) | 2016-05-19 | 2022-12-01 | 메타모딕스, 인코포레이티드 | Pyloric Anchor Recovery Tools and Methods |
CN109414582B (en) | 2016-06-27 | 2022-10-28 | 心脏起搏器股份公司 | Cardiac therapy system for resynchronization pacing management using subcutaneous sensing of P-waves |
WO2018009392A1 (en) | 2016-07-07 | 2018-01-11 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
CN109475743B (en) | 2016-07-20 | 2022-09-02 | 心脏起搏器股份公司 | System for utilizing atrial contraction timing references in a leadless cardiac pacemaker system |
EP3500342B1 (en) | 2016-08-19 | 2020-05-13 | Cardiac Pacemakers, Inc. | Trans-septal implantable medical device |
WO2018039335A1 (en) | 2016-08-24 | 2018-03-01 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using p-wave to pace timing |
EP3503970B1 (en) | 2016-08-24 | 2023-01-04 | Cardiac Pacemakers, Inc. | Cardiac resynchronization using fusion promotion for timing management |
WO2018057626A1 (en) | 2016-09-21 | 2018-03-29 | Cardiac Pacemakers, Inc. | Implantable cardiac monitor |
CN109803720B (en) | 2016-09-21 | 2023-08-15 | 心脏起搏器股份公司 | Leadless stimulation device having a housing containing its internal components and functioning as a terminal for a battery case and an internal battery |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
US10413733B2 (en) | 2016-10-27 | 2019-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
WO2018081133A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Implantable medical device having a sense channel with performance adjustment |
WO2018081275A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
AU2017350759B2 (en) | 2016-10-27 | 2019-10-17 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
EP3532160B1 (en) | 2016-10-27 | 2023-01-25 | Cardiac Pacemakers, Inc. | Separate device in managing the pace pulse energy of a cardiac pacemaker |
EP3532159B1 (en) | 2016-10-27 | 2021-12-22 | Cardiac Pacemakers, Inc. | Implantable medical device delivery system with integrated sensor |
EP3532158B1 (en) | 2016-10-31 | 2022-12-14 | Cardiac Pacemakers, Inc. | Systems for activity level pacing |
US10617874B2 (en) | 2016-10-31 | 2020-04-14 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10583301B2 (en) | 2016-11-08 | 2020-03-10 | Cardiac Pacemakers, Inc. | Implantable medical device for atrial deployment |
CN109952129B (en) | 2016-11-09 | 2024-02-20 | 心脏起搏器股份公司 | System, device and method for setting cardiac pacing pulse parameters for a cardiac pacing device |
US10881869B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Wireless re-charge of an implantable medical device |
US10639486B2 (en) | 2016-11-21 | 2020-05-05 | Cardiac Pacemakers, Inc. | Implantable medical device with recharge coil |
CN109996585B (en) | 2016-11-21 | 2023-06-13 | 心脏起搏器股份公司 | Implantable medical device with magnetically permeable housing and induction coil disposed around the housing |
CN109963618B (en) | 2016-11-21 | 2023-07-04 | 心脏起搏器股份公司 | Leadless cardiac pacemaker with multi-mode communication |
EP3541471B1 (en) | 2016-11-21 | 2021-01-20 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker providing cardiac resynchronization therapy |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
EP3573708B1 (en) | 2017-01-26 | 2021-03-10 | Cardiac Pacemakers, Inc. | Leadless implantable device with detachable fixation |
JP7000438B2 (en) | 2017-01-26 | 2022-01-19 | カーディアック ペースメイカーズ, インコーポレイテッド | Human device communication with redundant message transmission |
WO2018140623A1 (en) | 2017-01-26 | 2018-08-02 | Cardiac Pacemakers, Inc. | Leadless device with overmolded components |
JP6953614B2 (en) | 2017-04-03 | 2021-10-27 | カーディアック ペースメイカーズ, インコーポレイテッド | Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate |
US10905872B2 (en) | 2017-04-03 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device with a movable electrode biased toward an extended position |
US10918875B2 (en) | 2017-08-18 | 2021-02-16 | Cardiac Pacemakers, Inc. | Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator |
WO2019036600A1 (en) | 2017-08-18 | 2019-02-21 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
WO2019055434A1 (en) | 2017-09-13 | 2019-03-21 | CARDIONOMIC, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
US11235163B2 (en) | 2017-09-20 | 2022-02-01 | Cardiac Pacemakers, Inc. | Implantable medical device with multiple modes of operation |
US11185703B2 (en) | 2017-11-07 | 2021-11-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker for bundle of his pacing |
WO2019108545A1 (en) | 2017-12-01 | 2019-06-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker |
US11813463B2 (en) | 2017-12-01 | 2023-11-14 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with reversionary behavior |
WO2019108482A1 (en) | 2017-12-01 | 2019-06-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker |
EP3717059A1 (en) | 2017-12-01 | 2020-10-07 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker |
US11529523B2 (en) | 2018-01-04 | 2022-12-20 | Cardiac Pacemakers, Inc. | Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone |
CN111556773A (en) | 2018-01-04 | 2020-08-18 | 心脏起搏器股份公司 | Dual chamber pacing without beat-to-beat communication |
US11058880B2 (en) | 2018-03-23 | 2021-07-13 | Medtronic, Inc. | VFA cardiac therapy for tachycardia |
WO2019183507A1 (en) | 2018-03-23 | 2019-09-26 | Medtronic, Inc. | Av synchronous vfa cardiac therapy |
WO2019183512A1 (en) | 2018-03-23 | 2019-09-26 | Medtronic, Inc. | Vfa cardiac resynchronization therapy |
JP2021535776A (en) | 2018-08-13 | 2021-12-23 | カーディオノミック,インク. | Systems and methods that act on systole and / or relaxation |
CN112770807A (en) | 2018-09-26 | 2021-05-07 | 美敦力公司 | Capture in atrial-to-ventricular cardiac therapy |
US11951313B2 (en) | 2018-11-17 | 2024-04-09 | Medtronic, Inc. | VFA delivery systems and methods |
US11679265B2 (en) | 2019-02-14 | 2023-06-20 | Medtronic, Inc. | Lead-in-lead systems and methods for cardiac therapy |
EP3946556A1 (en) | 2019-03-29 | 2022-02-09 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11833349B2 (en) | 2019-03-29 | 2023-12-05 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
US11213676B2 (en) | 2019-04-01 | 2022-01-04 | Medtronic, Inc. | Delivery systems for VfA cardiac therapy |
SG11202111619WA (en) | 2019-05-06 | 2021-11-29 | Cardionomic Inc | Systems and methods for denoising physiological signals during electrical neuromodulation |
US11712188B2 (en) | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
US11305127B2 (en) | 2019-08-26 | 2022-04-19 | Medtronic Inc. | VfA delivery and implant region detection |
WO2021050679A1 (en) | 2019-09-11 | 2021-03-18 | Cardiac Pacemakers, Inc. | Tools and systems for implanting and/or retrieving a leadless cardiac pacing device with helix fixation |
US11571582B2 (en) | 2019-09-11 | 2023-02-07 | Cardiac Pacemakers, Inc. | Tools and systems for implanting and/or retrieving a leadless cardiac pacing device with helix fixation |
US11813466B2 (en) | 2020-01-27 | 2023-11-14 | Medtronic, Inc. | Atrioventricular nodal stimulation |
US11911168B2 (en) | 2020-04-03 | 2024-02-27 | Medtronic, Inc. | Cardiac conduction system therapy benefit determination |
US11813464B2 (en) | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Cardiac conduction system evaluation |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3835864A (en) * | 1970-09-21 | 1974-09-17 | Rasor Ass Inc | Intra-cardiac stimulator |
US5843132A (en) * | 1996-10-07 | 1998-12-01 | Ilvento; Joseph P. | Self-contained, self-powered temporary intravenous pacing catheter assembly |
US6214032B1 (en) * | 1996-02-20 | 2001-04-10 | Advanced Bionics Corporation | System for implanting a microstimulator |
US20010041930A1 (en) * | 1995-10-16 | 2001-11-15 | Medtronic, Inc. | Variable flexibility stent |
US20020090388A1 (en) * | 2000-12-01 | 2002-07-11 | Humes H. David | Intravascular drug delivery device and use therefor |
US20020183791A1 (en) * | 2001-01-16 | 2002-12-05 | Stephen Denker | Implantable defibrillator with wireless vascular stent electrodes |
US20030032892A1 (en) * | 2001-04-25 | 2003-02-13 | Erlach Julian Van | Nanodevices, microdevices and sensors on in-vivo structures and method for the same |
US20030158584A1 (en) * | 2002-02-19 | 2003-08-21 | Cates Adam W | Chronically-implanted device for sensing and therapy |
US20040249417A1 (en) * | 2003-06-04 | 2004-12-09 | Terrance Ransbury | Implantable intravascular device for defibrillation and/or pacing |
US20050043765A1 (en) * | 2003-06-04 | 2005-02-24 | Williams Michael S. | Intravascular electrophysiological system and methods |
US7003350B2 (en) * | 2003-11-03 | 2006-02-21 | Kenergy, Inc. | Intravenous cardiac pacing system with wireless power supply |
US7239921B2 (en) * | 2003-06-23 | 2007-07-03 | Alfred E. Mann Foundation For Scientific Research | Housing for an implantable medical device |
Family Cites Families (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3211154A (en) | 1962-06-25 | 1965-10-12 | Mine Safety Appliances Co | Sequence switch for ventricular defibrillator |
US3236239A (en) | 1962-07-17 | 1966-02-22 | American Optical Corp | Defibrillator |
US3258013A (en) | 1963-07-01 | 1966-06-28 | Zenith Radio Corp | Defibrillators |
US3389704A (en) | 1965-12-06 | 1968-06-25 | Zenith Radio Corp | Discharge circuit for a defibrillator |
USRE30366E (en) | 1970-09-21 | 1980-08-12 | Rasor Associates, Inc. | Organ stimulator |
DE2309749B2 (en) | 1973-02-27 | 1978-05-24 | Siegfried Dr.Med. Dipl.-Ing. Dipl.-Wirtsch.-Ing. Lehr | Electrode for medical purposes |
US3959706A (en) | 1973-08-25 | 1976-05-25 | Mabuchi Motor Co. Ltd. | Charger |
US3865101A (en) | 1974-05-01 | 1975-02-11 | Datascope Corp | Portable and separable heart monitor and heart defibrillator apparatus |
JPS5132926A (en) | 1974-09-14 | 1976-03-19 | Kogyo Gijutsuin | Fukusudenchi no haiburitsudoseigyohoshiki |
US4030509A (en) | 1975-09-30 | 1977-06-21 | Mieczyslaw Mirowski | Implantable electrodes for accomplishing ventricular defibrillation and pacing and method of electrode implantation and utilization |
US4041956A (en) | 1976-02-17 | 1977-08-16 | Coratomic, Inc. | Pacemakers of low weight and method of making such pacemakers |
JPS52151835A (en) | 1976-04-30 | 1977-12-16 | Univ Johns Hopkins | Enclosed battery |
US4096856A (en) | 1976-09-03 | 1978-06-27 | Physio-Control Corporation | Portable electronic physiological instrument having separable first and second components, and improved mechanical connector therefor |
US4900303A (en) | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4168711A (en) | 1978-06-08 | 1979-09-25 | American Optical Corporation | Reversal protection for RLC defibrillator |
SE434460B (en) | 1979-06-14 | 1984-07-30 | Bertil Reenstierna | ENDOCARDIAL, IMPLANTABLE CORD FOR THE HEART STIMULATOR |
US4323075A (en) | 1979-07-02 | 1982-04-06 | Mieczyslaw Mirowski | Battery failure compensation for a power supply used in an implantable defibrillator |
US4332259A (en) | 1979-09-19 | 1982-06-01 | Mccorkle Jr Charles E | Intravenous channel cardiac electrode and lead assembly and method |
US4326532A (en) | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
US4643201A (en) | 1981-02-02 | 1987-02-17 | Medtronic, Inc. | Single-pass A-V lead |
US4485813A (en) | 1981-11-19 | 1984-12-04 | Medtronic, Inc. | Implantable dynamic pressure transducer system |
US4414986A (en) | 1982-01-29 | 1983-11-15 | Medtronic, Inc. | Biomedical stimulation lead |
US4628944A (en) | 1982-02-08 | 1986-12-16 | Cordis Corporation | Cardiac pacing lead with biodegradable fixation structure |
US4708145A (en) | 1982-06-01 | 1987-11-24 | Medtronic, Inc. | Sequential-pulse, multiple pathway defibrillation method |
US4530550A (en) | 1982-09-13 | 1985-07-23 | Olympus Optical Company Ltd. | Power supply unit for electronic flash |
US4559951A (en) | 1982-11-29 | 1985-12-24 | Cardiac Pacemakers, Inc. | Catheter assembly |
US4931947A (en) | 1983-09-29 | 1990-06-05 | Engelhard Corporation | Fuel cell/battery hybrid system having battery charge-level control |
FR2561929B1 (en) | 1984-03-27 | 1989-02-03 | Atesys | IMPLANTED AUTOMATIC APPARATUS FOR VENTRICULAR DEFIBRILLATION |
US4892102A (en) | 1984-04-16 | 1990-01-09 | Astrinsky Eliezer A | Cardiac pacing and/or sensing lead and method of use |
US4687482A (en) | 1984-04-27 | 1987-08-18 | Scripps Clinic And Research Foundation | Vascular prosthesis |
US4510551A (en) | 1984-05-21 | 1985-04-09 | Endeco Canada Limited | Portable memory module |
US4727877A (en) | 1984-12-18 | 1988-03-01 | Medtronic, Inc. | Method and apparatus for low energy endocardial defibrillation |
US4635639A (en) | 1985-01-08 | 1987-01-13 | Physio-Control Corporation | Modular physiological instrument |
US4637397A (en) | 1985-05-30 | 1987-01-20 | Case Western Reserve University | Triphasic wave defibrillation |
US4722353A (en) | 1985-09-16 | 1988-02-02 | Intermedics, Inc. | Stabilizer for implantable electrode |
US4662377A (en) | 1985-11-07 | 1987-05-05 | Mieczyslaw Mirowski | Cardioverting method and apparatus utilizing catheter and patch electrodes |
US4827936A (en) | 1986-05-14 | 1989-05-09 | Ventritex | Apparatus for stimulating the heart with protected pacer |
US4736150A (en) | 1986-07-09 | 1988-04-05 | The United States Of America As Represented By The Secretary Of The Army | Method of increasing the useful life of rechargeable lithium batteries |
CA1308170C (en) | 1987-01-14 | 1992-09-29 | Rahul Mehra | Apparatus for defibrillating a heart |
US4953551A (en) | 1987-01-14 | 1990-09-04 | Medtronic, Inc. | Method of defibrillating a heart |
US5014696A (en) | 1987-01-14 | 1991-05-14 | Medtronic, Inc. | Endocardial defibrillation electrode system |
SE8800019D0 (en) | 1988-01-07 | 1988-01-07 | Knut Olof Edhag | FOR CARDIALLY DEFIBLATION USED INTRAVASCULES ELECTRO CABLE |
US4850357A (en) | 1988-01-12 | 1989-07-25 | Cardiac Pacemakers, Inc. | Biphasic pulse generator for an implantable defibrillator |
US5099838A (en) | 1988-12-15 | 1992-03-31 | Medtronic, Inc. | Endocardial defibrillation electrode system |
EP0373953A3 (en) | 1988-12-15 | 1992-03-04 | Medtronic, Inc. | Endocardial defibrillation electrode system |
US4969463A (en) | 1989-06-06 | 1990-11-13 | Cardiac Pacemakers, Inc. | Defibrillation electrode and method for employing gatling discharge defibrillation |
US4996984A (en) | 1989-09-26 | 1991-03-05 | Eli Lilly And Company | Defibrillation method |
US4991603A (en) | 1989-10-30 | 1991-02-12 | Siemens-Pacesetter, Inc. | Transvenously placed defibrillation leads via an inferior vena cava access site and method of use |
US4998975A (en) | 1989-10-30 | 1991-03-12 | Siemens-Pacesetter, Inc. | Travenously placed defibrillation leads |
US5044375A (en) | 1989-12-08 | 1991-09-03 | Cardiac Pacemakers, Inc. | Unitary intravascular defibrillating catheter with separate bipolar sensing |
US5269319A (en) | 1989-12-08 | 1993-12-14 | Cardiac Pacemakers, Inc. | Unitary intravascular defibrillating catheter with bipolar sensing |
US4998531A (en) | 1990-03-28 | 1991-03-12 | Cardiac Pacemakers, Inc. | Implantable N-phasic defibrillator output bridge circuit |
US5221261A (en) | 1990-04-12 | 1993-06-22 | Schneider (Usa) Inc. | Radially expandable fixation member |
US5133353A (en) | 1990-04-25 | 1992-07-28 | Cardiac Pacemakers, Inc. | Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode |
CA2081896A1 (en) | 1990-06-15 | 1991-12-16 | James E. Shapland | Drug delivery apparatus and method |
US5105810A (en) | 1990-07-24 | 1992-04-21 | Telectronics Pacing Systems, Inc. | Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker with means for minimizing bradycardia support pacing voltages |
US5163427A (en) | 1990-11-14 | 1992-11-17 | Medtronic, Inc. | Apparatus for delivering single and multiple cardioversion and defibrillation pulses |
US5170784A (en) | 1990-11-27 | 1992-12-15 | Ceon Ramon | Leadless magnetic cardiac pacemaker |
US5174288A (en) | 1990-11-30 | 1992-12-29 | Medtronic, Inc. | Method and apparatus for cardiac defibrillation |
US5129392A (en) | 1990-12-20 | 1992-07-14 | Medtronic, Inc. | Apparatus for automatically inducing fibrillation |
US5170802A (en) | 1991-01-07 | 1992-12-15 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5107834A (en) | 1991-01-30 | 1992-04-28 | Cardiac Pacemakers, Inc. | Low energy multiple shock defibrillation/cardioversion discharge technique and electrode configuration |
ES2134205T3 (en) * | 1991-03-08 | 1999-10-01 | Keiji Igaki | STENT FOR GLASSES, SUPPORT STRUCTURE FOR SAID STENT, AND DEVICE FOR MOUNTING SAID STENT. |
US5131388A (en) | 1991-03-14 | 1992-07-21 | Ventritex, Inc. | Implantable cardiac defibrillator with improved capacitors |
US5405363A (en) | 1991-03-15 | 1995-04-11 | Angelon Corporation | Implantable cardioverter defibrillator having a smaller displacement volume |
US5431686A (en) | 1992-02-18 | 1995-07-11 | Angeion Corporation | Method for optimal pulse defibrillation using an implantable defibrillator |
US5383907A (en) | 1992-12-18 | 1995-01-24 | Angeion Corporation | System and method for delivering multiple closely spaced defibrillation pulses |
US5235979B1 (en) | 1991-03-15 | 1994-11-01 | Angeion Corp | Dual battery system for implantable defibrillator |
US5342399A (en) | 1991-12-17 | 1994-08-30 | Angeion Corporation | Implantable defibrillator system having a small capacitance valve |
US5241960A (en) | 1992-07-08 | 1993-09-07 | Angeion Corporation | Defibrillator pulse generator |
US5407444A (en) | 1992-12-18 | 1995-04-18 | Angeion Corporation | Staged energy concentration for a defibrillator |
CA2106378A1 (en) | 1991-04-05 | 1992-10-06 | Tom D. Bennett | Subcutaneous multi-electrode sensing system |
WO1992020401A1 (en) | 1991-04-10 | 1992-11-26 | British Technology Group Usa, Inc. | Defibrillator and demand pacer catheter and method |
US5199429A (en) | 1991-05-23 | 1993-04-06 | Angemed, Inc. | Implantable defibrillator system employing capacitor switching networks |
US5144946A (en) | 1991-08-05 | 1992-09-08 | Siemens Pacesetter, Inc. | Combined pacemaker substrate and electrical interconnect and method of assembly |
WO1993006792A1 (en) * | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5269326A (en) | 1991-10-24 | 1993-12-14 | Georgetown University | Method for transvenously accessing the pericardial space via the right auricle for medical procedures |
US5358514A (en) | 1991-12-18 | 1994-10-25 | Alfred E. Mann Foundation For Scientific Research | Implantable microdevice with self-attaching electrodes |
US5193540A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5366443A (en) * | 1992-01-07 | 1994-11-22 | Thapliyal And Eggers Partners | Method and apparatus for advancing catheters through occluded body lumens |
US5231996A (en) | 1992-01-28 | 1993-08-03 | Medtronic, Inc. | Removable endocardial lead |
US5699796A (en) | 1993-01-29 | 1997-12-23 | Cardima, Inc. | High resolution intravascular signal detection |
CA2087132A1 (en) | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
US5261400A (en) | 1992-02-12 | 1993-11-16 | Medtronic, Inc. | Defibrillator employing transvenous and subcutaneous electrodes and method of use |
US5534015A (en) | 1992-02-18 | 1996-07-09 | Angeion Corporation | Method and apparatus for generating biphasic waveforms in an implantable defibrillator |
US5306291A (en) | 1992-02-26 | 1994-04-26 | Angeion Corporation | Optimal energy steering for an implantable defibrillator |
EP0559933A1 (en) | 1992-03-10 | 1993-09-15 | Pacesetter AB | Electrode assembly for an implantable defibrillator/cardioverter |
EP0559932A1 (en) | 1992-03-10 | 1993-09-15 | Pacesetter AB | Implantable assembly for defibrillating or cardioverting a heart |
US5372585A (en) | 1992-04-09 | 1994-12-13 | Tiefenbrun; Jonathan | Instrument and associated method for applying biologically effective composition during laparoscopic operation |
SE9201600L (en) | 1992-05-21 | 1993-11-22 | Siemens Elema Ab | The electrode device |
CA2138043A1 (en) | 1992-06-30 | 1994-01-06 | Gust H. Bardy | Method and apparatus for treatment of angina |
DE69307509T2 (en) | 1992-06-30 | 1997-07-31 | Medtronic Inc | DEVICE FOR THE TREATMENT OF HEART ERRORS |
US5292338A (en) | 1992-07-30 | 1994-03-08 | Medtronic, Inc. | Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use |
US5324309A (en) | 1992-09-25 | 1994-06-28 | Medtronic, Inc. | Overlapping pulse cardioversion or defibrillation |
EP0669839B2 (en) | 1992-10-01 | 2001-12-19 | Cardiac Pacemakers, Inc. | Stent-type defibrillation electrode structures |
SE9203735D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | ELECTRIC SYSTEM FOR DEFIBRILLATOR |
SE9203732D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | ELECTRIC SYSTEM FOR DEFIBRILLATOR |
SE9203733D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | defibrillation |
DE69428188T2 (en) | 1993-01-29 | 2002-03-21 | Medtronic Inc | MULTIPLE SENSOR FOR DISPLAYING ELECTRICAL SIGNALS IN BLOOD VESSELS |
US5706809A (en) | 1993-01-29 | 1998-01-13 | Cardima, Inc. | Method and system for using multiple intravascular sensing devices to detect electrical activity |
US5368588A (en) | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
US5879374A (en) | 1993-05-18 | 1999-03-09 | Heartstream, Inc. | External defibrillator with automatic self-testing prior to use |
US5314430A (en) | 1993-06-24 | 1994-05-24 | Medtronic, Inc. | Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use |
US5468254A (en) | 1993-07-26 | 1995-11-21 | Cardiac Pacemakers, Inc. | Method and apparatus for defibrillation using a multiphasic truncated exponential waveform |
US5593427A (en) | 1993-08-06 | 1997-01-14 | Heartstream, Inc. | Electrotherapy method |
US5607454A (en) | 1993-08-06 | 1997-03-04 | Heartstream, Inc. | Electrotherapy method and apparatus |
SE9303119D0 (en) | 1993-09-24 | 1993-09-24 | Siemens Elema Ab | defibrillator |
WO1995010989A1 (en) | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5445646A (en) * | 1993-10-22 | 1995-08-29 | Scimed Lifesystems, Inc. | Single layer hydraulic sheath stent delivery apparatus and method |
US5483165A (en) | 1994-01-14 | 1996-01-09 | Heartstream, Inc. | Battery system and method for determining a battery condition |
US5527358A (en) | 1994-01-21 | 1996-06-18 | Medtronic, Inc. | Temporary medical electrical lead |
US5487760A (en) | 1994-03-08 | 1996-01-30 | Ats Medical, Inc. | Heart valve prosthesis incorporating electronic sensing, monitoring and/or pacing circuitry |
US5957956A (en) | 1994-06-21 | 1999-09-28 | Angeion Corp | Implantable cardioverter defibrillator having a smaller mass |
US5645586A (en) | 1994-07-08 | 1997-07-08 | Ventritex, Inc. | Conforming implantable defibrillator |
NO300407B1 (en) * | 1994-08-30 | 1997-05-26 | Vingmed Sound As | Apparatus for endoscope or gastroscope examination of patients |
US5549115A (en) | 1994-09-28 | 1996-08-27 | Heartstream, Inc. | Method and apparatus for gathering event data using a removable data storage medium and clock |
US5591211A (en) | 1994-12-09 | 1997-01-07 | Ventritex, Inc. | Defibrillator having redundant switchable high voltage capacitors |
US5613935A (en) | 1994-12-16 | 1997-03-25 | Jarvik; Robert | High reliability cardiac assist system |
US5704910A (en) | 1995-06-05 | 1998-01-06 | Nephros Therapeutics, Inc. | Implantable device and use therefor |
US5716391A (en) | 1995-08-23 | 1998-02-10 | Medtronic, Inc. | Medical electrical lead having temporarily rigid fixation |
FR2742058B1 (en) | 1995-12-12 | 1998-03-06 | Ela Medical Sa | FOLDABLE ANCHOR BARS PROBES FOR AN IMPLANTED MEDICAL DEVICE, IN PARTICULAR FOR A HEART STIMULATOR |
SE9504675D0 (en) | 1995-12-28 | 1995-12-28 | Pacesetter Ab | Implantable electrode cable assembly with multiple electrode contact elements |
DE19609471A1 (en) | 1996-03-01 | 1997-11-13 | Biotronik Mess & Therapieg | Electrode arrangement |
US5833603A (en) | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
US5766224A (en) | 1996-04-02 | 1998-06-16 | Incontrol, Inc. | Temporary, post-heart surgery cardioverting and pacing system and lead systems for use therein |
US6783543B2 (en) | 2000-06-05 | 2004-08-31 | Scimed Life Systems, Inc. | Intravascular stent with increasing coating retaining capacity |
DE19626352A1 (en) | 1996-06-18 | 1998-01-02 | Biotronik Mess & Therapieg | Defibrillation electrode assembly |
US5807399A (en) | 1996-10-23 | 1998-09-15 | Medtronic, Inc. | Method for removal of chronically implanted leads and leads optimized for use therewith |
US5735887A (en) | 1996-12-10 | 1998-04-07 | Exonix Corporation | Closed-loop, RF-coupled implanted medical device |
DE19654491A1 (en) | 1996-12-17 | 1998-06-18 | Biotronik Mess & Therapieg | Stimulation electrode arrangement |
US5814089A (en) | 1996-12-18 | 1998-09-29 | Medtronic, Inc. | Leadless multisite implantable stimulus and diagnostic system |
ES2208963T3 (en) | 1997-01-03 | 2004-06-16 | Biosense, Inc. | PRESSURE SENSITIVE VASCULAR ENDOPROTESIS. |
US6164284A (en) | 1997-02-26 | 2000-12-26 | Schulman; Joseph H. | System of implantable devices for monitoring and/or affecting body parameters |
US7114502B2 (en) | 1997-02-26 | 2006-10-03 | Alfred E. Mann Foundation For Scientific Research | Battery-powered patient implantable device |
US5954761A (en) | 1997-03-25 | 1999-09-21 | Intermedics Inc. | Implantable endocardial lead assembly having a stent |
US5919210A (en) | 1997-04-10 | 1999-07-06 | Pharmatarget, Inc. | Device and method for detection and treatment of syncope |
US5769881A (en) | 1997-05-22 | 1998-06-23 | Sulzer Intermedics Inc. | Endocardial lead with multiple branches |
US6723121B1 (en) | 1997-06-18 | 2004-04-20 | Scimed Life Systems, Inc. | Polycarbonate-polyurethane dispersions for thrombo-resistant coatings |
US20020169493A1 (en) | 1997-07-10 | 2002-11-14 | Widenhouse Christopher W. | Anti-thrombogenic coatings for biomedical devices |
US5904707A (en) | 1997-08-15 | 1999-05-18 | Heartstream, Inc. | Environment-response method for maintaining an external medical device |
US5868792A (en) | 1997-08-15 | 1999-02-09 | Heartstream, Inc. | Environment-response method for maintaining electronic device such as an external defibrillator |
US6231516B1 (en) | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US5908447A (en) | 1998-02-06 | 1999-06-01 | Intermedics Inc. | Breakaway structure for body implantable medical device |
US20010044619A1 (en) | 1998-04-08 | 2001-11-22 | Peter A. Altman | Cardiac drug delivery system and method for use |
US6256541B1 (en) | 1998-04-17 | 2001-07-03 | Cardiac Pacemakers, Inc. | Endocardial lead having defibrillation and sensing electrodes with septal anchoring |
US6735474B1 (en) | 1998-07-06 | 2004-05-11 | Advanced Bionics Corporation | Implantable stimulator system and method for treatment of incontinence and pain |
US6141588A (en) | 1998-07-24 | 2000-10-31 | Intermedics Inc. | Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy |
US6256534B1 (en) | 1998-08-11 | 2001-07-03 | Angeion Corporation | Implantable defibrillator with countershock synchronized to P-wave |
US6119039A (en) | 1999-01-28 | 2000-09-12 | Heartstream, Inc. | Method and apparatus for delivering defibrillation energy |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6869440B2 (en) | 1999-02-09 | 2005-03-22 | Innercool Therapies, Inc. | Method and apparatus for patient temperature control employing administration of anti-shivering agents |
US6161029A (en) | 1999-03-08 | 2000-12-12 | Medtronic, Inc. | Apparatus and method for fixing electrodes in a blood vessel |
US20010041870A1 (en) | 1999-03-09 | 2001-11-15 | Edward M. Gillis | Implantable device for access to a treatment site |
US6319244B2 (en) | 1999-03-16 | 2001-11-20 | Chase Medical, L.P. | Catheter with flexible and rigid reinforcements |
US6304786B1 (en) | 1999-03-29 | 2001-10-16 | Cardiac Pacemakers, Inc. | Implantable lead with dissolvable coating for improved fixation and extraction |
DE19925853A1 (en) | 1999-06-02 | 2000-12-07 | Biotronik Mess & Therapieg | Cardioversion arrangement |
US6312378B1 (en) | 1999-06-03 | 2001-11-06 | Cardiac Intelligence Corporation | System and method for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care |
DE29909923U1 (en) | 1999-06-08 | 1999-09-02 | Schmitz Rode Thomas | Intravascularly implantable capsule with holding device for a miniaturized measuring system for the telemetric recording of medical parameters |
AU7354400A (en) * | 1999-09-03 | 2001-04-10 | A-Med Systems, Inc. | Guidable intravascular blood pump and related methods |
US7949395B2 (en) | 1999-10-01 | 2011-05-24 | Boston Scientific Neuromodulation Corporation | Implantable microdevice with extended lead and remote electrode |
US6330481B1 (en) | 1999-10-04 | 2001-12-11 | Medtronic Inc. | Temporary medical electrical lead having biodegradable electrode mounting pad |
US6383171B1 (en) * | 1999-10-12 | 2002-05-07 | Allan Will | Methods and devices for protecting a passageway in a body when advancing devices through the passageway |
EP1106202A3 (en) | 1999-11-30 | 2004-03-31 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Electrode for intravascular stimulation, cardioversion and /or defibrillation |
US6561975B1 (en) | 2000-04-19 | 2003-05-13 | Medtronic, Inc. | Method and apparatus for communicating with medical device systems |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US7006858B2 (en) | 2000-05-15 | 2006-02-28 | Silver James H | Implantable, retrievable sensors and immunosensors |
US6933822B2 (en) | 2000-05-24 | 2005-08-23 | Magtech As | Magnetically influenced current or voltage regulator and a magnetically influenced converter |
US6436068B1 (en) | 2000-08-24 | 2002-08-20 | Gust H. Bardy | Instrument for implanting sensors and solid materials in a subcutaneous location and method thereof |
AU2001286731A1 (en) | 2000-08-25 | 2002-03-04 | Kensey Nash Corporation | Covered stents, systems for deploying covered stents |
US6584362B1 (en) | 2000-08-30 | 2003-06-24 | Cardiac Pacemakers, Inc. | Leads for pacing and/or sensing the heart from within the coronary veins |
US6829504B1 (en) | 2000-09-14 | 2004-12-07 | Cardiac Pacemakers, Inc. | System and method for preventing recurrence of atrial tachyarrhythmia |
US7194302B2 (en) | 2000-09-18 | 2007-03-20 | Cameron Health, Inc. | Subcutaneous cardiac stimulator with small contact surface electrodes |
US7069080B2 (en) | 2000-09-18 | 2006-06-27 | Cameron Health, Inc. | Active housing and subcutaneous electrode cardioversion/defibrillating system |
US6721597B1 (en) | 2000-09-18 | 2004-04-13 | Cameron Health, Inc. | Subcutaneous only implantable cardioverter defibrillator and optional pacer |
US7120495B2 (en) | 2000-09-18 | 2006-10-10 | Cameron Health, Inc. | Flexible subcutaneous implantable cardioverter-defibrillator |
US7065407B2 (en) | 2000-09-18 | 2006-06-20 | Cameron Health, Inc. | Duckbill-shaped implantable cardioverter-defibrillator canister and method of use |
US7149575B2 (en) | 2000-09-18 | 2006-12-12 | Cameron Health, Inc. | Subcutaneous cardiac stimulator device having an anteriorly positioned electrode |
US7043299B2 (en) | 2000-09-18 | 2006-05-09 | Cameron Health, Inc. | Subcutaneous implantable cardioverter-defibrillator employing a telescoping lead |
US7039465B2 (en) | 2000-09-18 | 2006-05-02 | Cameron Health, Inc. | Ceramics and/or other material insulated shell for active and non-active S-ICD can |
US6778860B2 (en) | 2001-11-05 | 2004-08-17 | Cameron Health, Inc. | Switched capacitor defibrillation circuit |
US6754528B2 (en) | 2001-11-21 | 2004-06-22 | Cameraon Health, Inc. | Apparatus and method of arrhythmia detection in a subcutaneous implantable cardioverter/defibrillator |
US6952610B2 (en) | 2000-09-18 | 2005-10-04 | Cameron Health, Inc. | Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter- defibrillator |
US6937907B2 (en) | 2000-09-18 | 2005-08-30 | Cameron Health, Inc. | Subcutaneous electrode for transthoracic conduction with low-profile installation appendage and method of doing same |
US6834204B2 (en) | 2001-11-05 | 2004-12-21 | Cameron Health, Inc. | Method and apparatus for inducing defibrillation in a patient using a T-shock waveform |
US6950705B2 (en) | 2000-09-18 | 2005-09-27 | Cameron Health, Inc. | Canister designs for implantable cardioverter-defibrillators |
US7090682B2 (en) | 2000-09-18 | 2006-08-15 | Cameron Health, Inc. | Method and apparatus for extraction of a subcutaneous electrode |
US6988003B2 (en) | 2000-09-18 | 2006-01-17 | Cameron Health, Inc. | Implantable cardioverter-defibrillator having two spaced apart shocking electrodes on housing |
US7194309B2 (en) | 2000-09-18 | 2007-03-20 | Cameron Health, Inc. | Packaging technology for non-transvenous cardioverter/defibrillator devices |
US20020035381A1 (en) | 2000-09-18 | 2002-03-21 | Cameron Health, Inc. | Subcutaneous electrode with improved contact shape for transthoracic conduction |
US7076296B2 (en) | 2000-09-18 | 2006-07-11 | Cameron Health, Inc. | Method of supplying energy to subcutaneous cardioverter-defibrillator and pacer |
US6788974B2 (en) | 2000-09-18 | 2004-09-07 | Cameron Health, Inc. | Radian curve shaped implantable cardioverter-defibrillator canister |
US6866044B2 (en) | 2000-09-18 | 2005-03-15 | Cameron Health, Inc. | Method of insertion and implantation of implantable cardioverter-defibrillator canisters |
US6522926B1 (en) | 2000-09-27 | 2003-02-18 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US6845267B2 (en) | 2000-09-28 | 2005-01-18 | Advanced Bionics Corporation | Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation |
CA2430554A1 (en) | 2000-12-01 | 2002-07-25 | Nephros Therapeutics, Inc. | Intravascular blood conditioning device and use thereof |
US6509104B2 (en) | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
US6783499B2 (en) | 2000-12-18 | 2004-08-31 | Biosense, Inc. | Anchoring mechanism for implantable telemetric medical sensor |
US6704604B2 (en) | 2000-12-28 | 2004-03-09 | Medtronic, Inc. | System and method for promoting selective tissue in-growth for an implantable medical device |
US7519421B2 (en) | 2001-01-16 | 2009-04-14 | Kenergy, Inc. | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
US6735475B1 (en) | 2001-01-30 | 2004-05-11 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain |
US6901287B2 (en) | 2001-02-09 | 2005-05-31 | Medtronic, Inc. | Implantable therapy delivery element adjustable anchor |
US6520939B2 (en) | 2001-02-13 | 2003-02-18 | Scimed Life Systems, Inc. | Hemostasis valve |
US20020133224A1 (en) | 2001-03-13 | 2002-09-19 | Clara Bajgar | Drug eluting encapsulated stent |
US6501993B2 (en) | 2001-03-27 | 2002-12-31 | Pacesetter, Inc. | Electrode assembly with a detachable distal tip |
US6885895B1 (en) | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US6733485B1 (en) | 2001-05-25 | 2004-05-11 | Advanced Bionics Corporation | Microstimulator-based electrochemotherapy methods and systems |
WO2002098282A2 (en) | 2001-06-04 | 2002-12-12 | Albert Einstein Healthcare Network | Cardiac stimulating apparatus having a blood clot filter and atrial pacer |
US6671547B2 (en) | 2001-06-13 | 2003-12-30 | Koninklijke Philips Electronics N.V. | Adaptive analysis method for an electrotherapy device and apparatus |
US7054692B1 (en) | 2001-06-22 | 2006-05-30 | Advanced Bionics Corporation | Fixation device for implantable microdevices |
US6760622B2 (en) | 2001-07-03 | 2004-07-06 | Pacesetter, Inc. | Implantable multi-chamber cardiac stimulation device with sensing vectors |
US6726714B2 (en) | 2001-08-09 | 2004-04-27 | Scimed Life Systems, Inc. | Stent delivery system |
US7097665B2 (en) | 2003-01-16 | 2006-08-29 | Synecor, Llc | Positioning tools and methods for implanting medical devices |
US6776784B2 (en) | 2001-09-06 | 2004-08-17 | Core Medical, Inc. | Clip apparatus for closing septal defects and methods of use |
DE10153842A1 (en) | 2001-10-24 | 2003-05-08 | Biotronik Mess & Therapieg | electrode assembly |
WO2003082403A2 (en) * | 2002-03-27 | 2003-10-09 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control via coupled electrodes |
US7314484B2 (en) | 2002-07-02 | 2008-01-01 | The Foundry, Inc. | Methods and devices for treating aneurysms |
ATE536201T1 (en) | 2002-09-26 | 2011-12-15 | Pacesetter Inc | CARDIOVASCULAR ANCHORING DEVICE |
WO2004049919A2 (en) | 2002-12-04 | 2004-06-17 | Durect Corporation | Implant anchor and methods of use |
WO2004052452A1 (en) | 2002-12-09 | 2004-06-24 | Medtronic, Inc. | Reducing relative intermodule motion in a modular implantable medical device |
US20050165469A1 (en) | 2002-12-24 | 2005-07-28 | Michael Hogendijk | Vascular prosthesis including torsional stabilizer and methods of use |
WO2004064084A2 (en) | 2003-01-03 | 2004-07-29 | Nucore, Inc. | Self-damped inductor |
US7155293B2 (en) | 2003-01-29 | 2006-12-26 | Cardiac Pacemakers, Inc. | Medical electrical lead employing load bearing sleeve |
US6932930B2 (en) | 2003-03-10 | 2005-08-23 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US8239045B2 (en) | 2003-06-04 | 2012-08-07 | Synecor Llc | Device and method for retaining a medical device within a vessel |
US20050004639A1 (en) | 2003-07-03 | 2005-01-06 | Advanced Neuromodulation Systems, Inc. | Medical lead with resorbable material |
US20050080472A1 (en) | 2003-10-10 | 2005-04-14 | Atkinson Robert Emmett | Lead stabilization devices and methods |
EP1682215B1 (en) | 2003-10-24 | 2008-12-24 | Cardiac Pacemakers, Inc. | Myocardial lead attachment system |
WO2005058415A2 (en) | 2003-12-12 | 2005-06-30 | Synecor, Llc | Implantable medical device having pre-implant exoskeleton |
US8309112B2 (en) | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
ATE534426T1 (en) | 2004-02-10 | 2011-12-15 | Synecor Llc | INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS |
US8489189B2 (en) | 2004-10-29 | 2013-07-16 | Medtronic, Inc. | Expandable fixation mechanism |
US8308794B2 (en) | 2004-11-15 | 2012-11-13 | IZEK Technologies, Inc. | Instrumented implantable stents, vascular grafts and other medical devices |
US7072171B1 (en) | 2006-02-13 | 2006-07-04 | Wilson Greatbatch Technologies, Inc. | Electrolytic capacitor capable of insertion into the vasculature of a patient |
-
2004
- 2004-12-10 WO PCT/US2004/041324 patent/WO2005058415A2/en active Application Filing
- 2004-12-10 US US11/009,649 patent/US7747335B2/en not_active Expired - Fee Related
- 2004-12-10 EP EP04813627A patent/EP1701766A2/en not_active Withdrawn
- 2004-12-10 CA CA002549006A patent/CA2549006A1/en not_active Abandoned
- 2004-12-10 JP JP2006543996A patent/JP2007514482A/en active Pending
- 2004-12-10 AU AU2004298995A patent/AU2004298995A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/981,363 patent/US20080065051A1/en not_active Abandoned
- 2007-10-31 US US11/981,008 patent/US20080058886A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3835864A (en) * | 1970-09-21 | 1974-09-17 | Rasor Ass Inc | Intra-cardiac stimulator |
US20010041930A1 (en) * | 1995-10-16 | 2001-11-15 | Medtronic, Inc. | Variable flexibility stent |
US6214032B1 (en) * | 1996-02-20 | 2001-04-10 | Advanced Bionics Corporation | System for implanting a microstimulator |
US5843132A (en) * | 1996-10-07 | 1998-12-01 | Ilvento; Joseph P. | Self-contained, self-powered temporary intravenous pacing catheter assembly |
US20020090388A1 (en) * | 2000-12-01 | 2002-07-11 | Humes H. David | Intravascular drug delivery device and use therefor |
US20020183791A1 (en) * | 2001-01-16 | 2002-12-05 | Stephen Denker | Implantable defibrillator with wireless vascular stent electrodes |
US20030032892A1 (en) * | 2001-04-25 | 2003-02-13 | Erlach Julian Van | Nanodevices, microdevices and sensors on in-vivo structures and method for the same |
US20030158584A1 (en) * | 2002-02-19 | 2003-08-21 | Cates Adam W | Chronically-implanted device for sensing and therapy |
US20040249417A1 (en) * | 2003-06-04 | 2004-12-09 | Terrance Ransbury | Implantable intravascular device for defibrillation and/or pacing |
US20050043765A1 (en) * | 2003-06-04 | 2005-02-24 | Williams Michael S. | Intravascular electrophysiological system and methods |
US7082336B2 (en) * | 2003-06-04 | 2006-07-25 | Synecor, Llc | Implantable intravascular device for defibrillation and/or pacing |
US7529589B2 (en) * | 2003-06-04 | 2009-05-05 | Synecor Llc | Intravascular electrophysiological system and methods |
US7239921B2 (en) * | 2003-06-23 | 2007-07-03 | Alfred E. Mann Foundation For Scientific Research | Housing for an implantable medical device |
US7003350B2 (en) * | 2003-11-03 | 2006-02-21 | Kenergy, Inc. | Intravenous cardiac pacing system with wireless power supply |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040249431A1 (en) * | 2003-06-04 | 2004-12-09 | Terrance Ransbury | Device and method for retaining a medical device within a vessel |
US8239045B2 (en) | 2003-06-04 | 2012-08-07 | Synecor Llc | Device and method for retaining a medical device within a vessel |
US20090281521A1 (en) * | 2003-06-04 | 2009-11-12 | Williams Michael S | Method and apparatus for retaining medical implants within body vessels |
US7840282B2 (en) | 2003-06-04 | 2010-11-23 | Synecor Llc | Method and apparatus for retaining medical implants within body vessels |
US20050154437A1 (en) * | 2003-12-12 | 2005-07-14 | Williams Michael S. | Implantable medical device having pre-implant exoskeleton |
US7747335B2 (en) | 2003-12-12 | 2010-06-29 | Synecor Llc | Implantable medical device having pre-implant exoskeleton |
US20070265673A1 (en) * | 2006-04-03 | 2007-11-15 | Terrance Ransbury | Flexible interconnect assembly for implantable medical devices |
US20110071585A1 (en) * | 2006-12-04 | 2011-03-24 | Terrance Ransbury | Intravascular implantable device having superior anchoring arrangement |
US20080167702A1 (en) * | 2006-12-04 | 2008-07-10 | Terrance Ransbury | Intravascular implantable device having superior anchoring arrangement |
US8311633B2 (en) | 2006-12-04 | 2012-11-13 | Synecor Llc | Intravascular implantable device having superior anchoring arrangement |
US20100318166A1 (en) * | 2009-06-12 | 2010-12-16 | Terrance Ransbury | Methods and systems for anti-thrombotic intravascular implantable devices |
US20160023003A1 (en) * | 2012-07-17 | 2016-01-28 | Laura Tyler Perryman | Miniature implantable device and methods |
US10245436B2 (en) * | 2012-07-17 | 2019-04-02 | Stimwave Technologies Incorporated | Miniature implantable device and methods |
US11027139B2 (en) | 2012-12-05 | 2021-06-08 | Stimwave Technologies Incorporated | Miniature implantable device and methods |
US10674928B2 (en) | 2014-07-17 | 2020-06-09 | Medtronic, Inc. | Leadless pacing system including sensing extension |
US10390720B2 (en) | 2014-07-17 | 2019-08-27 | Medtronic, Inc. | Leadless pacing system including sensing extension |
US9399140B2 (en) | 2014-07-25 | 2016-07-26 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
USRE48197E1 (en) | 2014-07-25 | 2020-09-08 | Medtronic, Inc. | Atrial contraction detection by a ventricular leadless pacing device for atrio-synchronous ventricular pacing |
US9808628B2 (en) | 2014-11-11 | 2017-11-07 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9724519B2 (en) | 2014-11-11 | 2017-08-08 | Medtronic, Inc. | Ventricular leadless pacing device mode switching |
US10279168B2 (en) | 2014-11-11 | 2019-05-07 | Medtronic, Inc. | Leadless pacing device implantation |
US9623234B2 (en) | 2014-11-11 | 2017-04-18 | Medtronic, Inc. | Leadless pacing device implantation |
US9492669B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9492668B2 (en) | 2014-11-11 | 2016-11-15 | Medtronic, Inc. | Mode switching by a ventricular leadless pacing device |
US9289612B1 (en) | 2014-12-11 | 2016-03-22 | Medtronic Inc. | Coordination of ventricular pacing in a leadless pacing system |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
Also Published As
Publication number | Publication date |
---|---|
EP1701766A2 (en) | 2006-09-20 |
US20050154437A1 (en) | 2005-07-14 |
US7747335B2 (en) | 2010-06-29 |
JP2007514482A (en) | 2007-06-07 |
CA2549006A1 (en) | 2005-06-30 |
WO2005058415A3 (en) | 2005-09-09 |
WO2005058415A2 (en) | 2005-06-30 |
AU2004298995A1 (en) | 2005-06-30 |
US20080065051A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7747335B2 (en) | Implantable medical device having pre-implant exoskeleton | |
US8239045B2 (en) | Device and method for retaining a medical device within a vessel | |
US7734343B2 (en) | Implantable intravascular device for defibrillation and/or pacing | |
US10537731B2 (en) | Transvenous mediastinum access for the placement of cardiac pacing and defibrillation electrodes | |
US9545512B2 (en) | Method and apparatus for retaining medical implants within body vessels | |
US7899554B2 (en) | Intravascular System and Method | |
US10850067B2 (en) | Implantation of an active medical device using the intercostal vein | |
US7363082B2 (en) | Flexible hermetic enclosure for implantable medical devices | |
US8311633B2 (en) | Intravascular implantable device having superior anchoring arrangement | |
US20110125246A1 (en) | Delivery tools and methods for intravascular implantable devices | |
AU2020397967A1 (en) | Implantable endovascular, low profile intracardiac left atrial restraining devices for low energy atrial cardioversion, pacing and sensing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |